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Abstract 
 
An emerging hypothesis in Parkinson’s disease (PD) is that dopaminergic (DA) 
neurons degenerate through a “dying back” axonopathy wherein degeneration begins in 
the distal axon and progresses over time towards the cell body. Impaired axonal 
transport also appears to play an early, pivotal role in PD. Thus processes that delay 
axonal transport dysfunction and/or axonal degeneration might slow PD progression. 
Previously, we and others have found that the WldS mouse mutant (“Wallerian 
degeneration-slow”), which exhibits delayed axonal degeneration after peripheral 
axonopathy, also protects DA terminal fields from the PD-mimetics 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) in vivo. To 
understand the mechanisms underlying WldS-mediated axonal protection, we tested 
whether WldS rescued DA neurons in vitro after treatment with either MPP+, the active 
component of MPTP, or 6-OHDA. WldS, but not its component parts, UbE4b and 
Nmnat1, robustly rescued neurites in dissociated DA cultures following either MPP+ or 6-
OHDA treatment. To extend these results, compartmented chambers were developed 
such that axons could be segregated from cell bodies and dendrites. Using these 
devices, we found that MPP+ impaired mitochondrial, but not synaptic vesicle transport, 
in DA axons and that WldS rescued MPP+-mediated impairment of mitochondrial 
transport in DA axons. Mechanistically, this appears to be due to WldS-mediated 
protection from toxin-induced loss of mitochondrial membrane potential. These results 
extend WldS protection to CNS DA neurons and suggest that WldS confers a gain-of-
function phenotype that attenuates mitochondrial dysfunction. This study, together with 
the large amount of evidence suggesting PD is associated with axonal “dying-back”, also 
underscores the necessity of developing therapeutics aimed at axons as well as cell 
bodies so as to preserve circuitry and function. 
iii 
 
Acknowledgements 
 
 This dissertation is dedicated to my children, Mackenzie Josephine Antenor-
Dorsey and Jameson Connor Antenor-Dorsey. Always remember that both of you are 
my ultimate pride and joy, now and forever. Mommy loves both of you … A LOT.  
 I want to thank my husband, Michael Dorsey. From being my “sugar daddy”, to 
my first “victim” for a talk, to the ultimate back massager, I know I could not have 
survived this journey without you. Thank you for being a loving father, a sweet husband, 
and being my best friend. We make cute kids, don’t we? I love you so much. 
To my Nanay and Tatay, who have sacrificed so much of their lives in order to 
help me succeed in pursuing a career as a scientist, maraming salamat po. I owe you 
(and continue to owe you) so much. Both of you are such great role models for my 
brother and I to exemplify. Mahal na mahal ko po kayo.   
I’d like to thank my Ate Linda, my second mother. She may be half my height, but 
her love for my brother and I know no bounds. She is the epitome of “small, but fierce”, 
and I miss her so much. I promise, I’ll come home soon! 
 I’d also like to thank my Kuya (brother), who helped me get started on my 
science career by making my PowerPoint presentations for my National Science Fair 
competitions back in the Philippines.  
I like to extend my gratitude to the rest of my family and my friends, especially: 
Amanda, the godmother of my children and my sister from another mother, Alison, a true 
friend who always puts up with my venting, Cass, who is always supportive and initiates 
the best “themed” lunches for the 9th floor, Indra, a selfless friend and my fashionably 
fabulous cheerleader, Jen, who gave great and helpful suggestions on my dissertation, 
and Tunde, who always supplied me with compliments and comic books, the two things 
a geeky girl can never be without. You guys made my life, inside and outside the lab, full 
of laughter and joy, and I thank you.  
I’d like to thank all the past and present members of the O’Malley Lab. A shout-
out is in order to the undergrad students who were instrumental in getting my huge data 
sets analyzed: Manouela Valtcheva, Diane Ma, and Anna Dardick. I’d also like to thank 
iv 
 
Steve Harmon for assisting me in the lab, especially in regards to maintaining my mice 
colony and for teaching me about my bread and butter in the lab, primary midbrain 
cultures. I’d also like to thank Dr. Ivy Jong, who was helpful in giving me the tools to 
transform myself from a systems neuroscientist into a cell neuroscientist. Finally, I’d like 
to express my utmost gratitude to Dr. Jeong Sook Kim-Han, whose generosity knows no 
bounds. I thank you for teaching me so much about science, but I am most grateful for 
your insight on family and God. You have made me into a stronger Catholic scientist, 
and I cannot repay you enough for that.   
 I’d also like to extend my gratitude to past and present members of my 
committee, Dr. Guojun Bu and Dr. Valeria Cavalli, who gave me helpful discussions 
about my science, Dr. Paul Kotzbauer, who let me rotate in his lab, Dr. Aaron DiAntonio 
and Dr. Marc Diamond, who may have “joined” the party later but gave such insightful 
suggestions, and Dr. Joel Perlmutter, who always believed in me.  
I want to express my sincere thanks to my thesis mentor, Dr. Karen O’Malley, for 
giving me the opportunity to be part of her lab. I am very grateful for the mentorship and 
guidance she has provided me over the past 5 years. She gave me the freedom to learn 
and grow as a scientist, but was always there with a helping and guiding hand when I 
needed it.  
Finally, I’d like to thank my Lord and Savior, Jesus Christ. All things are possible 
through You. To God be the Glory.  
 
 
 
 
 
 
 
 
 
v 
 
Table of Contents 
Abstract …………………………………………………………………………. ii 
Acknowledgements ……………………………………………………………. iv 
Table of Contents …………………………………………………………….... v 
List of Tables ………………………………………………………………….... viii 
List of Figures …………………………………………………………………..  ix 
 
Chapter 1: Introduction ………………………………………………………… 1 
1.1 Parkinson’s disease: Overview …………………………………...……… 2 
1.2 Genetic Factors ……………………………………………………………. 3 
 1.2.1 -synuclein ………………………………………………………. 4 
 1.2.2 LRRK2 …………………………………………………………….  4 
 1.2.3 Parkin …………………………………………………………….. 5 
 1.2.4 PINK1 …………………………………………………………….. 6 
1.3 Toxin Models ………………………………………………………………. 7 
 1.3.1 MPTP and MPP+ ………………………………………………… 7 
 1.3.2 6-OHDA …………………………………………………………... 8 
1.4 Axonal dysfunction in PD …………………………………………………. 10 
 1.4.1 Post-mortem PD patient data ………………………………….. 10 
 1.4.2 Functional imaging data ………………………………………… 11 
 1.4.3 Genetic studies ………………………………………………….. 12 
 1.4.4 Toxin studies …………………………………………………….. 14 
 1.4.5 Programmed cell death versus axonal degeneration ……….. 15 
1.5 Wallerian degeneration slow (WldS) mice ………………………………. 16 
 1.5.1 Ube4b …………………………………………………………….. 18 
 1.5.2 Nmnat1 …………………………………………………………… 19 
 1.5.3 Axonal structure and function …………………………………. 20 
 1.5.4 Mitochondrial function ………………………………………….. 21 
1.6 Goals of the current study ……………………………………………….. 23 
References …………………………………………………………………….. 25 
Chapter 2: WldS but not Nmnat1 protects dopaminergic neurites from MPP+ 
        toxicity ……………………………………………………………... 36 
Abstract ………………………………………………………………………... 37 
2.1 Introduction ……………………………………………………………….. 38 
2.2 Materials and methods ………………………………………………….. 40 
 2.2.1 Cell culture and toxin treatment ……………………………… 40 
 2.2.2 Lentiviral infection of DA neurons ……………………………. 42 
 2.2.3 Immunocytochemistry …………………………………………. 42 
 2.2.4 Western Blotting ……………………………………………….. 43 
 2.2.5 Statistical analysis ……………………………………………... 44 
2.3 Results …………………………………………………………………….. 44 
 2.3.1 WldS protects cell bodies and neurites from MPP+ …………. 44 
 2.3.2 Cytoplasmic WldS protects cell bodies and neurites against  
           MPP+ …………………………………………………….. 45 
 2.3.3 Nmnat1 does not protect against MPP+ toxicity ……………. 45 
 2.3.4 Inactive WldS protects cell bodies and neurites against  
vi 
 
                    MPP+ …………………………………………………………….. 46 
 2.3.5 NAD+ protects cell bodies and neurites against MPP+ …….. 47 
 2.3.6 SIRT1 is not responsible for the NAD+-mediated protection 
                    of cell bodies and neurites against MPP+ ………………….... 47 
 2.3.7 NAD+ and WldS effects are additive ………………………….. 48 
2.4 Discussion …………………………………………………………………. 49 
2.5 Acknowledgements ……………………………………………………….. 53 
References ……………………………………………………………………… 54 
Chapter 3: WldS but not Nmnat1 protects dopaminergic neurites from  
                  6-OHDA toxicity …………………………………………………… 76 
Abstract ………………………………………………………………………... 77 
3.1 Introduction ……………………………………………………………….. 78 
3.2 Materials and methods ………………………………………………….. 81 
3.3 Results …………………………………………………………………….. 81 
 3.3.1 WldS protects cell bodies and neurites from 6-OHDA………. 81 
 3.3.2 Nmnat1 does not protect DA neurons against 6-OHDA 
                     toxicity …………………………………………………………… 82 
 3.3.3 NAD+ does not protect DA cell bodies and neurites against  
                    6-OHDA toxicity …………………………………………………. 82 
3.4 Discussion …………………………………………………………………. 83 
3.5 Acknowledgements ………………………………………………………. 87 
References …………………………………………………………………….. 88 
Chapter 4: The Parkinsonian Mimetic, MPP+, specifically impairs  
                  Mitochondrial Transport in Dopamine Axons …………………. 99 
Abstract ………………………………………………………………………… 100 
4.1 Introduction ………………………………………………………………... 101 
4.2 Materials and Methods …………………………………………………... 103 
 4.2.1 Cell culture and microchamber devices ……………………… 103 
 4.2.2 Determination of cell viability ………………………………….. 104 
 4.2.3 Quantification of tubulin ………………………………………… 104 
 4.2.4 Autophagy ……………………………………………………….. 105 
 4.2.5 Optical imaging …………………………………………………. 105 
 4.2.6 Image analysis ………………………………………………….. 106 
 4.2.7 [3H]Dopamine release …………………………………………. 101 
 4.2.8 Mitochondrial membrane potential and size ………………… 107 
 4.2.9 Statistical analysis ……………………………………………… 107 
4.3 Results …………………………………………………………………….. 108 
 4.3.1 MPP+ causes neuritic degeneration and autophagy before 
                    cell body loss ……………………………………………………. 108 
 4.3.2 MPP+ disrupts mitochondrial axonal transport ………………. 110 
 4.3.3 MPP+ does not affect vesicular transport ……………………. 113 
 4.3.4 MPP+ rapidly depolarizes axonal mitochondria ……………… 114 
 4.3.5 Thiol-based reagents rescue disrupted transport, neurites,  
          and cells …………………………………………………………. 115 
 4.3.6 DA mitochondria are smaller and slower than non-DA  
          mitochondria …………………………………………………….. 117 
vii 
 
4.4 Discussion …………………………………………………………………. 118 
4.5 Acknowledgements ………………………………………………………. 123 
References …………………………………………………………………….. 124  
Chapter 5: WldS protects dopaminergic axons from MPP+-induced changes in 
        mitochondrial transport …………………………………………… 146 
Abstract …………………………………………………………………………. 147 
5.1 Introduction ………………………………………………………………… 148 
5.2 Materials and methods …………………………………………………… 151 
 5.2.1 Western Blotting ………………………………………………… 152 
 5.2.2 Immunohistochemistry …………………………………………. 152 
 5.2.3 Fragmentation of axons ………………………………………… 152 
5.3 Results ……………………………………………………………………… 153 
 5.3.1 WldS prevents MPP+-induced changes in axonal structure … 153 
 5.3.2 WldS protein is preset in DA mitochondria ……………………. 154 
 5.3.3 WldS prevents MPP+-induced changes in axonal 
          mitochondrial transport ………………………………………….. 155 
 5.3.4 WldS prevents MPP+-induced decreases in axonal  
          mitochondrial membrane potential ……………………………... 156 
 5.3.5 WldS protects DA neurons against MPP+-induced autophagy.. 157 
5.4 Discussion ………………………………………………………………….. 157 
5.5 Acknowledgements ………………………………………………………… 162 
References ……………………………………………………………………… 163 
Chapter 6: Conclusions and Future Directions ……………………………… 178 
6.1 Conclusions …………………………………………………………………  179 
6.2 Future Directions …………………………………………………………… 183 
 6.2.1 Does disruption of the mitochondrial permeability transition  
        pore in DA neurons inhibit the protective effect of WldS? … 183  
6.2.2 Does WldS protect DA neurons through an effect on glutathione  
          levels? …………………………………………………………….. 184  
6.2.3 How does WldS protect against 6-OHDA-mediated  
         neurodegeneration? …………………………………………….. 185 
6.2.3.1 Does WldS protect DA neurons against oxidative  
           stress? ………………………………………………….. 185 
6.2.3.2 Does WldS protect DA neurons against upregulation   
 of UPR? ………………………………………………… 186 
6.2.3.3 Does WldS protect DA neurons against activation of  
            p53? ........................................................................... 187 
6.2.3.4 Does WldS protect against decreased mitochondrial  
            membrane potential due to 6-OHDA toxicity? ………. 187 
6.2.4 Does 6-OHDA affect axonal mitochondrial dynamics? ……… 188 
6.2.5 Does MPTP affect mitochondrial motility and velocity in vivo?. 189 
6.2.6 Does WldS protect against MPTP-induced changes in   
          mitochondrial motility and velocity in vivo? ………………….. 190 
References ……………………………………………………………………… 192 
      
  
viii 
 
List of Tables 
Table 4.1 Effect of substrates, inhibitors, and anti-oxidants on  
                MPP+-disrupted mitochondrial axonal transport …………………. 128 
Table 4.2 DA axons exhibit unique mitochondrial and vesicular  
                characteristics .............................................................................. 129 
Table 4.3 MPP+ did not affect mitochondrial number, speed or size in  
                non-DA axons ……………………………………………………….. 130 
Table 5.1 WT and WldS have similar mitochondrial characteristics ………. 167 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Figures 
Figure 1.1 Mouse WldS fusion protein structure ……………………………. 22 
Figure 2.1 Wlds protects DA neurons from MPP+ toxicity………………….. 60 
Figure 2.2 Cytoplasmic Wlds protects DA neurons from MPP+ toxicity ….. 62 
Figure 2.3 Nmnat by itself does not protect DA neurons from MPP+  
                 toxicity ………………………………………………………………. 64 
Figure 2.4 WldS and cytoplasmic Nmnat1 protect DRG axons from  
                 vincristine …………………………………………………………… 66 
Figure 2.5 Inactive WldS also protects DA neurons from MPP+ toxicity ….. 68 
Figure 2.6 NAD+ protects DA cells and neurites from MPP+ toxicity ……… 70 
Figure 2.7 NAD+ does not protect DA neurons through the SIRT1  
                 pathway …………………………………………………………….. 72 
Figure 2.8 The protective effect of NAD+ and WldS are additive …………. 74 
Figure 3.1 Wlds protects DA neurons from 6-OHDA toxicity………………. 93 
Figure 3.2 Nmnat1 by itself does not protect DA neurons from 6-OHDA  
                  toxicity ……………………………………………………………… 95 
Figure 3.3 NAD+ does not protect DA cells and neurites from 6-OHDA  
                  toxicity ....................................................................................... 97 
Figure 4.1 Neurite degeneration, microtubule disruption, and autophagy  
                 Precede DA cell death following MPP+ treatment ……………… 131 
Figure 4.2 MPP+ rapidly decreases mitochondrial movement in DA  
                 axons as shown by mtDendra2 ………………………………....... 134 
Figure 4.3 MPP+ rapidly decreases mitochondrial movement in DA  
                 axons as shown by MitoTracker Red …………………………….  136 
Figure 4.4 MPP+ does not affect axonal movement of synaptic vesicles … 138 
Figure 4.5 MPP+ rapidly leads to DA efflux ………………………………….. 140 
Figure 4.6 MPP+ rapidly depolarizes DA mitochondria ……………………..  142 
Figure 4.7 NAC protects DA cell bodies and neurites from MPP+-induced  
                 degeneration ………………………………………………………… 144  
Figure 5.1 Wlds prevents changes in axonal structure after MPP+ ………… 168 
Figure 5.2 Wlds partially colocalizes to axonal mitochondria ……………….. 170 
Figure 5.3 Wlds protects against MPP+-induced changes in mitochondrial  
       axonal transport …………………………………………………….. 172 
Figure 5.4 Wlds prevents MPP+-induced decreases in axonal mitochondrial 
                 membrane potential ………………………………………………… 174 
Figure 5.5 Wlds prevents mitophagy after MPP+ …………………………….. 176 
Figure 6.1 Proposed model of how WldS protects DA axons from PD  
                  mimetics …………………………………………………………….. 182 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
Introduction  
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1.1  Parkinson’s disease: Overview 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease in the United States. Presenting late in life, it affects 1% of the population 
over the age of 55. This progressive neurodegenerative disease is characterized 
by the loss of dopaminergic neurons in the substantia nigra (SN) which project to 
the striatum [1-2].  PD is also associated with the formation of cytoplasmic 
inclusions in the nervous system called Lewy bodies. Lewy bodies are spherical 
eosinophilic aggregates composed of proteins such as α-synuclein, parkin, and 
ubiquitin [4].  Striatal dopamine (DA) deficiency results in diminished motor 
control in PD, characterized by resting tremor, rigidity, bradykinesia and postural 
instability [5-6]. These motor symptoms do not appear until there is 
approximately a 30% loss of DA neurons and about 50-60% loss of DA [7]. 
Although positron emission tomography (PET) imaging shows decreased 
fluorodopa uptake in the striatum indicating a loss of DA innervation, the clinical 
diagnosis of PD can only be confirmed by post-mortem pathology. 
PD-related neurodegeneration extends beyond the DA neurons of the SN. 
It is evident in noradrenergic [8], serotonergic [9], and cholinergic systems [10] as 
well as the cerebral cortex, olfactory bulb and autonomic nervous system [5]. In 
fact, the earliest pathology of PD is the presence of thread-like inclusion bodies, 
or Lewy neurites, in the axons of peripheral neurons [5]. Moreover, degeneration 
of hippocampal structures and cholinergic inputs to the cortex have been known 
to contribute to the comorbidity of dementia in PD [11].  
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At present, there is no known cure for PD. Current treatments target 
replenishment of striatal DA via administration of the DA precursor, levodopa, 
which initially alleviates most of the symptoms of PD. However, this treatment 
does not prevent or slow the progression of the disease. It often produces severe 
dyskinetic side effects and may decrease in efficacy throughout disease 
progression [12]. The etiology of PD is still unknown, but much about PD has 
been learned from epidemiological studies, post-mortem studies, and animal 
model systems.  
 
1.2  Genetic factors  
 Genetic studies of individuals with familial PD have led to the identification 
of fifteen loci (PARK1-15) that are linked to PD [13]. Genes associated with the 
disease at eleven of these loci have been identified: α-synuclein, Parkin, α-
synuclein duplications and triplications, ubiquitin C-terminal hydrolase L1 (UCH-
L1), PTEN-induced putative kinase 1 (PINK1), DJ-1, leucine-rich repeat kinase 2 
(LRRK2), ATP13A2, Omi/HtrA2, PLA2G6, and FBXO7.  Although the majority of 
PD cases are idiopathic, studies on mutations in the α-synuclein, Parkin, PINK1, 
and LRRK2 genes that lead to familial PD have given clues to the molecular 
mechanisms that result in DA cell loss in PD. 
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1.2.1  -synuclein 
Missense mutations in the gene encoding α-synuclein (A53T, A30P and 
E46K) and triplications of a portion of α-synuclein have been linked to autosomal 
dominant PD [14-18]. α-synuclein is a presynaptic protein of unknown function, 
but is abundant in the brain and associated with vesicles and membranes. Thus, 
it is thought to be involved in synaptic vesicle trafficking, storage and 
compartmentalization of neurotransmitters [19-22], perhaps as a co-chaperone 
[18]. Because α-synuclein tends to aggregate, it has been implicated in PD 
pathogenesis. This is consistent with studies showing that α-synuclein is the 
major fibrillar component of Lewy bodies in both familial and sporadic PD [4].   
 
1.2.2  LRRK2 
 Mutations in LRRK2 are the most common known cause of late-onset 
autosomal dominant PD and are seen in idiopathic cases of PD [23-25]. LRRK2 
is a multi-domain protein that contains a Rho/Ras-like GTPase domain, a 
MAPKKK kinase domain, a WD40-repeat domain, a leucine-rich repeat domain, 
and a C-terminal of RAS domain. LRRK2 is expressed in forebrain structures 
including nigrostriatal DA neurons and localizes to the Golgi, synaptic vesicles, 
plasma membrane, lysosomes and outer mitochondrial membranes [26-31]. 
Although the function of LRRK2 is unknown, deletion of the LRRK2 homolog, 
LRK-1, in C. elegans leads to depletion of synaptic vesicle proteins [32]. LRRK2 
has also been shown to associate with lipid rafts, localize to Lewy bodies and 
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regulate neurite length and branching [33-35]. The G2019S and I2020T 
mutations are located in the kinase domain and are associated with increased 
kinase activity [36-39]. Many studies have shown that alterations in the kinase 
activity of LRRK2 due to disease-linked mutations affect apoptosis and 
neurodegeneration; however it is unclear how these changes in kinase activity 
lead to PD [38-40]. 
 
1.2.3  Parkin 
A loss-of-function mutation in the parkin gene was identified at the PARK2 
locus and linked to autosomal recessive juvenile parkinsonism (AR-JP) [41]. 
Mutations in Parkin are one of the most common known genetic causes of early-
onset PD. Parkin is an E3 ubiquitin-protein ligase that acts in conjunction with E2 
ubiquitin-conjugating enzymes to target proteins for degradation via the 
proteasome by adding ubiquitin chains to specific substrates [42-44]. Mutations 
associated with AR-JP disrupt the E3 ligase activity of parkin, preventing the 
targeting of specific proteins to the proteasome. Parkin is neuroprotective against 
a variety of toxic insults in DA neurons [45].  Post-translation modifications of 
parkin by oxidative stress can inhibit its protective function by impairing its E3 
ligase activity [46-47]. Recent data suggests that Parkin is neuroprotective 
through its action on mitochondria. Data from Drosophila and mammalian 
neuronal cell lines indicates that Parkin is recruited to the mitochondria following 
the loss of its membrane potential (m) in response to various toxic insults. 
Relocated Parkin serves as a signal for the induction of  mitophagy, suggesting 
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that loss of Parkin activity allows the accumulation of dysfunctional mitochondria 
that leads to neuron loss in PD [48]. Therefore, another role of Parkin may be to 
monitor activity and maintain mitochondrial fidelity by triggering mitophagy if 
necessary.  
 
1.2.4  PINK1  
Loss-of-function mutations in PINK1 cause autosomal recessive early 
onset PD and are found in rare sporadic early onset cases [49-50]. PINK1 is a 
serine/threonine kinase that localizes to the mitochondrial intermembrane space 
and membranes of the mitochondria [49]. PINK1 is thought to play a role in cell 
death pathways as wild-type PINK1 can protect against staurosporine-induced 
cytochrome-c release but PD-linked mutations do not. [51]. Data suggest that 
PINK1’s kinase activity may play a role in mitochondrial biogenesis and function 
[52-53]. In flies, loss of PINK1 by siRNA causes mitochondrial dysfunction and 
DA cell loss which is rescued by overexpression of Parkin [54-56], suggesting 
that PINK1 is upstream of Parkin. Due to its high turnover rate, PINK1 is normally 
present at only low levels on bioenergetically active mitochondria. Mitochondrial 
depolarization leads to PINK1’s stabilization and accumulation on mitochondria. 
In turn, PINK1 accumulation appears to recruit Parkin to mitochondria in various 
cell lines inducing mitophagy. So PINK1 may also protect DA neurons by 
activating the removal of damaged mitochondria [57].  
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1.3  Toxin Models  
Epidemiological data on PD suggests that various environmental toxins 
may also play a role in the etiology of the disease. A number of Parkinsonian 
mimetics have been identified, of which, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or its active metabolite spell out  (MPP+) and 6-
hydroxydopamine (6-OHDA) are the two most commonly used. Each of these 
toxins has been shown to recapitulate, many, but not all, of the behavioral, 
pharmacological, and pathological hallmarks that characterize PD.  
 
1.3.1 MPTP and MPP+ 
 MPTP, a meperidine analog, mimics both the motor deficits and pathology 
characteristic of PD in humans [58-59]. Accidental ingestion of MPTP by humans 
led to motor deficits characteristic of PD. Similar to PD patients, these patients 
responded to L-DOPA treatment and DA agonist therapy [59]. Autopsy on one 
patient confirmed severe loss of DA neurons in the SN, but a noticeable lack of 
Lewy bodies, in comparison to what is seen in bona fide PD [58].  
 Administration of MPTP to non-human primates and rodents also 
produces PD-like symptoms which respond positively to L-DOPA and selective 
DA loss [60]. There is specific loss of DA neurons in the SN with a more dramatic 
reduction of striatal axons and DA levels that persist following MPTP exposure in 
mice [61-62]. Cytoplasmic inclusions have been shown to develop in MPTP-
treated primates [63], although traditional Lewy bodies have not been described 
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[64]. A robust inflammatory response has been shown, including chronic 
microgliosis and astrocytosis, which contributes to DA cell loss, as microglial 
inhibition protects DA neurons following MPTP administration in rodents [65].  
 MPTP is able to cross the blood-brain barrier and is rapidly converted to 
MPP+ by monoamine oxidase B (MAOB) in glial cells [66]. Despite expression of 
MAOB and production of MPP+ in non-DA neurons, MPP+ toxicity is specific to 
catecholaminergic neurons because of its high affinity for the DA plasma 
membrane transporter (DAT) and other catecholamine uptake systems. In in vitro 
systems, direct application of MPP+ induces cell death specifically in DA neurons. 
Inside the cell, MPP+ is sequestered into vesicles by the vesicular monoamine 
transporter (VMAT2), displacing DA [67]. MPP+ that is not sequestered into 
vesicles can enter mitochondria where it inhibits complex I of the electron 
transport chain. This leads to ATP depletion, generation of reactive oxygen 
species (ROS) and cell death [1, 68]. 
 
1.3.2  6-OHDA 
6-OHDA is a neurotoxin formed from the auto-oxidation of DA and is found 
endogenously in the nigrostriatal pathway [69]. 6-OHDA was the first toxin used 
in an animal model to study neurodegeneration in PD [70]. Since 6-OHDA cannot 
cross the blood-brain barrier, experimental models of PD require that it is 
stereotactically injected into the striatum, the SN or the medial forebrain bundle 
(MFB). Similar to MPTP, rodent models utilizing 6-OHDA also lead to depletion of 
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striatal DA and degeneration of striatal nerve terminals followed by retrograde 
degeneration of neurons in the SN [71] 
The specificity of 6-OHDA in vivo towards catecholaminergic cells is due 
to its structural similarity to DA and norepinephrine. 6-OHDA is taken up by 
catecholaminergic neurons specifically by the DAT and noradrenergic transporter 
[72]. Once uptake into DA nerve terminals occurs, 6-OHDA accumulates in the 
cytosol and generates ROS by conversion into hydroxyl radicals and 6-OHDA 
quinone [73]. Inhibition of 6-OHDA uptake by catecholamine uptake inhibitors 
blocks 6-OHDA-induced toxicity in vivo [74]. 6-OHDA also induces cell death in 
primary mesencephalic cultures; however, because it is readily oxidized to 
hydrogen peroxide in tissue culture buffers, 6-OHDA is not selective for DA 
neurons in vitro [75].  
6-OHDA inhibits mitochondrial complex I in cell-free assays [76]. However, 
in whole cells, 6-OHDA does not cause ATP depletion [77], suggesting that this 
is not its main mechanism of action. 6-OHDA induces a collapse in m in 
primary DA cultures that is dependent on ROS [78] and p53 [79]. 6-OHDA 
treatment also causes release of cytochrome C, activation of caspase 3, DNA 
fragmentation [80] and damage [79], and annexin V staining [78], consistent with 
an apoptotic type of cell death.  
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1.4 Axonal dysfunction in PD 
Although the molecular mechanisms underlying the etiology of PD remain 
unclear, the genetic factors and toxin models previously discussed support the 
contention that four possibly interchangeable mechanisms underlie PD. These 
include: (1) death via impairment of the ubiquitin proteasome system (UPS), 
wherein increased levels of misfolded proteins overwhelm the UPS and 
accumulate as aggregates in the neuron; (2) death via impairment of 
mitochondrial function, specifically, inhibition of mitochondrial complex I leading 
to decreased ATP levels and increased levels of ROS; (3) death via oxidative 
stress due to internal DA autooxidation, mitochondrial dysfunction, or external 
oxidative stresses, and (4) neuroinflammation. Although all of these models may 
be true for the death of DA cell bodies, a new emerging hypothesis regarding DA 
dysfunction is based on the “dying-back” pattern of neuronal degeneration seen 
in PD models. In this model, axonal degeneration begins distally and progresses 
proximally over a period of time. This model hypothesizes that the initial insult in 
PD occurs at the level of the axon, rather than at the cell body.  
 
1.4.1  Post-mortem PD patient data 
Initial support for this hypothesis comes from studies on post-mortem PD 
patient brains. As described, Braak et al. have reported that the earliest 
pathology of PD is the presence of Lewy neurites in the dorsal motor nucleus and 
preganglionic axons of the vagal nerve [5]. These data suggest that the axonal 
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compartment is affected very early in the disease process. By observing patterns 
of -synuclein pathology and tyrosine hydroxylase (TH) immunostaining in the 
cardiac sympathetic axons and ganglia of PD patients, Orimo et al. proposed that 
the PD disease process begins in the distal axon and proceeds retrogradely [81]. 
In the DA system, dystrophic neurites have been described in the caudate 
nucleus of post-mortem brains from PD patients [82]. In addition, multiple studies 
done on postmortem brains of PD patients have observed an 80% loss of 
putamenal DA [6] and a 68-82% decrease in DA levels in the caudate of PD 
patients [83] with only a corresponding 30% cell death in SN neurons [84-86] at 
the time of onset of PD motor symptoms. Although postmortem studies may be 
subject to misinterpretation due to the effects of postmortem delay, measurement 
of another DA marker, VMAT binding, in postmortem caudate of PD patients and 
controls led Scherman et al. to conclude that PD motor signs become apparent 
when there is about a 50% decrease in VMAT binding relative to age-matched 
controls [85]. Consequently, either study revealed significantly more loss of 
nigrostriatal terminal field markers compared to the loss of SN DA neurons in PD. 
Taken together, the patient data suggest that the initial insult in PD occurs at the 
axon versus the cell body.        
 
1.4.2  Functional imaging data 
Numerous studies have also examined the relationship between DA 
terminal loss and the onset of PD symptoms using radioligand imaging. Three 
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types of PET radioligands have been used to assess striatal degeneration: (1) 
18F-dopa to assess L-dopa metabolism, (2) ligands to assess DAT binding, and 
(3) ligands to assess VMAT2 binding [87]. A 20-50% decrease in putamenal DA 
has been reported with 18F-dopa [88-91], while a 50-70% decrease in putamenal 
DA was seen using ligands for either DAT or VMAT2 [90, 92-93]. The 
discrepancy between neurotransmitter levels versus transporter levels may be 
due to a compensatory upregulation of aromatic acid decarboxylase resulting in 
the underestimation of terminal losses by 18F-dopa PET [87, 90]. But the 50-
70% striatal DA loss measured by DAT or VMAT radioligands is consistent with 
the 50% striatal DA loss seen in postmortem studies. In addition, both sets of 
data show a greater decrease of striatal DA versus the 30% loss of DA neurons 
seen in the SN at disease symptom onset. Hence, functional imaging data 
provide further support for the idea that degeneration of the axon plays an 
important role in the pathogenesis of the disease.  
  
1.4.3 Genetic studies 
Early evidence for axonal degeneration is also apparent in several PD-
linked gene models. For example, post mortem studies of patients with an -
synuclein gene triplication reveal widespread and severe neuritic pathology [94]. 
Dystrophic neurites are also evident in transgenic mice and primate models that 
overexpress -synuclein [95-96]. Transgenic mice exhibiting the mutant -
synuclein gene associated with familial PD (A53T) exhibit intra-axonal 
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accumulation of a-synuclein aggregates, vesicles, mitochondria, vacuoles and 
neurofilaments, suggesting an interruption of axonal transport and, subsequently, 
axonal degeneration [97-98]. Moreover, overexpression of -synuclein causes 
neurite degeneration in primary neuronal cultures [99] as well as defective axonal 
transport [100]. The latter may be due to the reported association of -synuclein 
with complexes containing the molecular motors kinesin and dynein that are 
responsible for microtubule-based axonal transport [101]. This suggests that 
axonal transport dysfunction can lead to axonal degeneration and that defective 
axonal transport may play a role in the etiology of PD.  
Mice expressing the PD-associated LRRK2 mutation (R1441G) exhibit 
PD-like motor symptoms that respond to L-dopa. These mice do not have SN DA 
neuron loss but exhibit fragmented DA axons that have axonal spheroids and 
form dystrophic neurites [102]. Meanwhile, the G2019S and I2020T LRRK2 
mutations exhibit dramatic reductions in neurite length and branching yet only 
slight changes in cell soma diameter in primary neuronal cultures [35]. Similar 
findings were made for the G2019S mutant in differentiated neuroblastoma cells 
[103] and in primary neurons derived from transgenic mice [104]. In addition, 
Parkin protects DA neurons against colchicine, a known microtubule-
depolymerizing agent [105]. Lastly, PINK1 may also play a role in axonal 
trafficking and hence the health of the axonal compartment via its association 
with Miro and Milton, two proteins that are involved in axonal mitochondrial 
transport [106]. Taken together, these data support the notion that there are 
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persistent early changes in axonal health and trafficking in PD, changes that may 
contribute to PD pathogenesis. 
1.4.4  Toxin studies 
 A similar pattern of neurodegeneration is also evident in toxin models of 
PD. For example, severe terminal field loss yet relatively mild nigral changes are 
also observed in response to MPTP treatment in primates [107-108]. This 
specific terminal field effect is consistent with data showing that this toxin can 
destabilize microtubules in cell-free assays, affect tubulin levels in differentiated 
PC12 cells [109-110], and impede the clearance of -synuclein by impairing 
dynein activity [111]. More directly, MPP+ affects axonal transport in the squid 
giant axon by increasing retrograde transport and decreasing anterograde 
transport independent of the cell’s ATP production [112]. In the mammalian PC12 
cell line MPP+ also affects axonal mitochondrial trafficking by destabilizing 
microtubules [113]. Thus, toxin models of PD also support the idea that axonal 
transport dysfunction, and subsequent axonal degeneration, is important in the 
progression of PD.  
Rodent models lesioned with 6-OHDA also lead to depletion of striatal 
nerve terminals followed by retrograde degeneration of neurons in the SN [71]. 
Like MPP+, 6-OHDA also destabilizes microtubules in in vitro cell-free assays 
suggesting that microtubule destabilization is a common pathway to axon 
degeneration [114]. Consistent with this notion, rotenone, another well known PD 
mimetic, was reported to induce DA neuron death through microtubule 
depolymerization [115]. In addition, rotenone impairs mitochondrial transport in 
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differentiated SH-SY5Y cells, a neuroblastoma cell line that exhibits a DA 
phenotype [116]. Finally, intrastriatal injection of colchicines blocks retrograde 
axonal transport and subsequently causes degeneration of the striatonigral 
pathway [117]. Therefore, changes in axonal structure or transport can potentially 
mediate the “dying back” mechanism observed in PD.   
Taken together, there is a growing body of data from post mortem studies, 
genetic and toxin models indicating that axon dysfunction plays a key role in PD.  
 
1.4.5 Programmed cell death versus axonal degeneration 
It was initially thought that axons were highly dependent on cell bodies for 
long-term survival. However, recent studies reveal the existence of axon-
autonomous mechanism(s) that regulate rapid axon degeneration after injury 
[118]. For example,  axons of sympathetic neurons die back after localized NGF 
withdrawal, while the cell body survives [119]. In contrast, local application of 
NGF to the axonal terminal promotes survival of both the axon and cell body 
[120]. More directly, caspase-3, which is involved in programmed cell death, is 
not activated in a variety of axonal degeneration models [121]. In the context of 
PD, Ries et al. examined how c-jun N-terminal kinases (JNKs), which play a 
central role in mitogen-activated protein kinase (MAPK)-mediated apoptosis of 
SN DA neurons, affect 6-OHDA-mediated degeneration of DA axons. They found 
that homologous JNK2/JNK3 null mice show almost complete protection of their 
SN cell bodies but no protection of axons against 6-OHDA [122]. Further 
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evidence that axons can survive even in the presence of cell body death is seen 
from Wallerian degeneration-slow (WldS) mice. This mutation arose 
spontaneously from C57/Bl/6 mice and has been demonstrated to cause delayed 
Wallerian degeneration in the peripheral nerve after axotomy [123]. Studies show 
that the cell bodies of sympathetic neurons from WldS mice degenerate with a 
normal timecourse and morphology but that WldS neurites remain metabolically 
active in response to injury [124]. These studies suggest that the degeneration of 
neurites and cell bodies occur through mutually exclusive processes, and that the 
protection of one compartment does not necessarily lead to protection of the 
other.   
 
1.5  Wallerian degeneration-slow (WldS) mice  
Wallerian degeneration is similar to the “dying back” phenomenon in that 
the distal stump of an injured axon degenerates first. This occurs in four phases: 
1) the distal stump loses the ability to transmit action potentials; 2) the axon and 
synaptic terminals fragment; 3) the cytoskeleton degenerates; and 4) Schwann 
cells and invading macrophages remove axonal and nerve terminal debris [125]. 
As their names suggests, WldS mice exhibit delayed degeneration of neurites 
following  axotomy  or vincristine treatment but does not delay neuronal cell 
death following such insults [123]. This phenomenon is also observed in other 
axon disease models. For example, in the mouse model for progressive motor 
neuron (pmn) disease, crossing WldS mice with pmn mice protects neurites but 
not cell bodies against degeneration [126]. In contrast,, crossing pmn mice with 
17 
 
mice overexpressing Bcl-2, an anti-apoptotic protein, protects motorneuron cell 
bodies but not axonal degeneration [127]. These results suggest that Wallerian 
degeneration appears to occur through a different mechanism than apoptosis. 
WldS mice also protect axons in  other disease models such as myelin-
related axonopathy [128], gracile axonal dystrophy [129], autoimmune 
encephalomyelitis [130], ischemia [131], Alzheimer’s disease [132], and the toxin 
models of PD [62, 133]. In terms of the latter, Sajadi et al. have shown that unlike 
wild type mice, WldS preserves nigrostriatal projections but not SN cell bodies 
following 6-OHDA administration [133]. Similarly, Hasbani and O’Malley 
observed an even more pronounced preservation of terminal fields after MPTP 
treatment in WldS versus wild type animals [62]. Taken together, these data 
suggest that understanding the mechanisms underlying WldS axon protection 
may aid in the development of potential therapies for many neurodegenerative 
diseases, including PD. 
The WldS gene encodes an in-frame fusion protein of the amino (N)-
terminal 70 (N70) amino acids of ubiquination factor E4B (Ube4b), which is linked 
by a unique 18-amino acid region to the complete coding region of the 
nicotinamide adenine dinucleotide (NAD+) synthesizing enzyme, nicotinamide 
adenylytransferase 1 (Nmnat1) [134] (Figure 1). The fusion protein is localized to 
the nucleus due to the nuclear localization signal present on the Nmnat1 portion 
of the protein [135]. Coleman and colleagues have shown that transgenic 
animals expressing this fusion protein recapitulate the WldS phenotype [136]. At 
present, the components of the WldS sequence that are required for axon 
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protection and which downstream factors are involved in this process remains 
controversial. Several mechanistic hypotheses have been proposed.   
 
1.5.1  Ube4b 
Because inhibiting UPS delays axonal degeneration [136], the Ube4b part 
of the WldS fusion protein may be responsible for its neuroprotective effect. 
However, the WldS fusion gene contains only the first 70 amino acids of Ube4b, 
not the 123 amino acid sequence essential for its ubiquination activity. Hence, 
gain of multi-ubiquitination function is unlikely as the WldS protein lacks the U-box 
motif. Dominant-negative inhibition of Ube4b is another possibility since 
expression of the yeast deubiquitinating enzyme UBP2 delays axonal 
degeneration in olfactory receptor neurons [137]. However, Ufd2, the yeast 
homologue of Ube4b, is a positive survival factor [138] and inhibition of UPS  is 
linked to neurodegeneration rather than neuroprotection [139]. UPS has also 
been shown to be required for both developmental neuronal pruning and injury-
induced axon degeneration, while WldS has no effect on neuronal pruning [137]. 
Moreover, overexpression of Ube4b does not protect differentiated Neuro2A cells 
against vincristine [140] or dorsal root ganglion cells (DRGs) against axotomy 
[141].  
Although Ube4b activity may not be critical to WldS actions, the deletion of 
16 amino acids (N16) of the Ube4b portion of WldS completely suppresses the 
axon protection afforded by WldS in mice [142] and greatly weakens the 
protection of axons in Drosophila [143]. Mechanistically, the N16 portion of the 
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fusion protein co-immunoprecipitates with valosin containing protein (VCP/p97) 
[144]. VCP is a AAA-ATPase with key roles in UPS and membrane fusion [145]. 
Consequently, although WldS lacks Ube4b’s ligase activity, it maintains its ability 
to bind VCP which may target the fusion protein to areas critical for its activity.  
 
1.5.2  Nmnat1 
In contrast to Ube4b, in certain experimental paradigms the Nmnat1 
portion of WldS is sufficient for axon protection in vitro, acting either through the 
silent information regulator (SIRT1) [146] or through local NAD+ synthesis in 
neurites [147]. Consistent with Nmnat1’s NAD+ synthesizing capabilities, 
exogenous application of NAD+ can protect DRGs against degeneration [141]. 
Not all studies have shown the same results, however, even in the same model 
system [148]. In support of a model requiring the complete WldS fusion protein, 
transgenic mice that only overexpress Nmnat1 show normal rates of Wallerian 
degeneration [148]. However, cytoplasmically [149] or axonally targeted Nmnat1 
transgenic animals [150] are equally if not more effective at protecting at least 
peripheral model systems than WldS. Thus, cell type specific effects must exist 
with needing the complete WldS fusion gene to protect some axons but have 
Nmnat1 to be sufficient in other cases. 
Disparity in results hold true in Drosophila, as well since Avery et al. [151], 
showed that Nmnat’s enzymatic activity is required to protect axons following 
axotomy whereas Zhai et al., [152] found that Nmnat does not need its catalytic 
domain to protect axons. The latter study [152], as well as a new study 
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demonstrating that Nmnat also protects dendrites [153], both indicate that Nmnat 
exhibits a separate chaperone-like activity which protects axons and dendrites 
[152, 154]. These studies support the role of Nmnat in protecting against 
degeneration, but not though its traditional role in NAD+ synthesis. 
  Two other isoforms of Nmnat exist, Nmnat2 and Nmnat3. Nmnat2 is highly 
expressed in the brain compared to Nmnat1 and 3 and is primarily localized in 
the Golgi complex [155]. Overexpression of Nmnat2 protects DRG and superior 
cervical ganglia (SCG) axons following  axotomy  [156]  [157]. In either case, 
protection is dependent upon Nmnat2’s NAD+ synthesizing activity [156,157]. 
Similar results are true for Nmnat3, a mitochondrially localized isoform of Nmnat 
[158]. Nmnat3 is thought to promote axonal protection by mitigating the effects of 
ROS [159]. Based on these studies, it appears that the site of action plays a role 
in Nmnat’s effectiveness in protecting against axonal degeneration [160].  
Despite the data in Drosophila, in peripheral vertebrate model systems it 
appears that the NAD+ enzymatic activity of WldS is required since mutating key 
amino acids abolishes the neuroprotection [135-136]. Collectively, these studies 
suggest that the fusion protein has acquired a gain of function not normally 
present in the neuron and that the entire fusion gene is necessary for protection.  
 
1.5.3 Axonal structure and function 
Other studies have attempted to determine how the WldS protein protects 
through a more localized analysis of its effects on the axon. Suzuki et al. found 
that microtubule acetylation, a post-translational modification associated with 
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microtubule stability, is enhanced in cultured cerebellar granule cells in WldS mice 
[161]. In other studies, activation of SIRT2, a NAD+-dependent tubulin 
deacetylase, abolishes WldS resistance to axonal degeneration by colchicine 
[162]. Specific to PD, inhibition of SIRT2 using small interfering RNA rescued 
cells from -synuclein mediated toxicity [163]. These data suggest that the 
neuroprotective effect of WldS may be mediated by its effect on microtubule 
stabilization.  
Consistent with a role in stabilizing microtubule tracks, a microarray study 
using WldS mice crossed with pmn mice reported that 56 genes were 
differentially expressed between pmn and pmn x WldS mice [164]. None of the 
canonical “apoptosis” genes were altered, rather a large proportion of the genes 
that were upregulated were related to retrograde and anterograde transport (e.g. 
dynactin and kinesin) [164]. These studies suggest that WldS protects axons by 
maintaining proper axonal transport after injury.  
 
1.5.4 Mitochondrial function 
Mitochondrial dysfunction appears to be an early event in the 
degeneration of neurites [165]. For example, treatment of SCG neurons with the 
microtubule-disrupting agent, vinblastine, decreases m and induces neurite 
degeneration. In contrast, WldS mice maintain their m and have intact neurites 
leading to the proposal that preservation of m may mediate the axonal 
protection seen with WldS [166]. Recently, Barrientos et al. reported that WldS is 
able to regulate the mitochondrial permeability transition pore and prevent 
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calcium release, ATP loss, oxidative stress and release of proteins involved in 
axonal degeneration [167]. Although WldS is primarily in the nucleus, it appears 
to associate with mitochondria, albeit in lower levels than seen in the nucleus 
[162]. In addition, differential proteomics analysis comparing WT and WldS 
striatal synaptosomes identified 16 protein that were differentially expressed, 8 of 
which are mitochondrially-associated proteins [132]. Finally, Shen et al. has 
shown that WldS preserves mitochondrial trafficking in isolated cortical axons 
during chemical ischemia [168]. Taken together, WldS may protect axons by 
preserving or enhancing mitochondrial function.  
Collectively, the current body of literature suggest that WldS may protect 
axons by (1) preventing a decline in energy, (2) preventing degradation of axonal 
structure, (3) preventing the impairment of key motor proteins involved in axonal 
transport, and/or (4) by priming mitochondria to have a more robust response to 
degeneration-inducing stimuli.  
 
 
 
 
 
Fig 1.1 - Mouse WldS fusion protein structure (GenBank accession number 
AAG17285). Amino acid residue numbers relative to Ube4b and Nmnat1 are 
shown. From Fainzilber (2006) [3]. 
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1.6  Goals of the current study 
Observations from work done by our lab [62] and others [5, 169] have 
suggested that, in PD, DA neurons degenerate through a “dying back” 
axonopathy wherein degeneration begins in the distal axon and progresses over 
time towards the cell body. Therefore, processes that delay axonal degeneration 
might slow PD progression. Previous work in our lab has demonstrated that WldS 
mice protect DA terminal fields in the striatum from MPTP injury [62]. At present, 
the mechanisms underlying WldS-mediated axonal protection are unclear. Some 
studies have attributed WldS neuroprotection to the Nmnat1 portion of the protein 
while others have observed upregulation in genes involved in axonal structure 
and transport in WldS mice compared to controls. More recently, WldS’ action on 
the mitochondria has been suggested to be important component of its 
neuroprotective effect. It is unknown at this time which, if any, of these 
mechanisms underlies WldS protection of DA axons. Consequently, the overall 
goals of this work are to 1) test the hypothesis that the entire WldS fusion protein 
is required for axonal protection from parkinsonian mimetics in DA neurons, and 
2) to test the hypothesis that WldS protects DA axons by directly affecting axonal 
mitochondria such that they are not impaired following toxin treatment. 
With these goals in mind, we discuss which portion of the WldS gene 
protects DA neurites from MPP+ and 6-OHDA toxicity in Chapters 2 and 3, 
respectively. In addition, we test the neuroprotective effects of other isoforms of 
Nmnat in DA neurons as well as whether exogenous addition of NAD+ and NAD+ 
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precursors are sufficient to protect DA neurons against MPP+ and 6-OHDA in a 
similar manner to WldS neurons.  
 To study the effects of WldS specifically on DA axonal structure and 
function, we describe a novel system to segregate DA axons from the cell bodies 
in Chapter 4. Using this unique compartmented chamber, we test the hypothesis 
that impaired axonal transport plays a role in MPP+-induced axonal degeneration. 
Finally, we evaluate whether WldS is able to prevent the changes in mitochondrial 
motility and velocity observed in wild type DA axons after MPP+ treatment in 
Chapter 5.  
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Abstract 
The WldS mouse mutant (“Wallerian degeneration-slow”) delays axonal 
degeneration in a variety of disorders including in vivo models of Parkinson’s 
disease. The mechanisms underlying WldS-mediated axonal protection are 
unclear, although many studies have attributed WldS neuroprotection to the 
NAD+-synthesizing Nmnat1 portion of the fusion protein. Here, we used 
dissociated dopaminergic (DA) cultures to test the hypothesis that catalytically 
active Nmnat1 protects DA neurons from toxin-mediated axonal injury. Using 
mutant mice and lentiviral transduction of DA neurons, the present findings 
demonstrate that WldS but not Nmnat1, Nmnat3, or cytoplasmically-targeted 
Nmnat1 protects DA axons from the parkinsonian mimetic N-methyl-4-
phenylpyridinium (MPP+). Moreover, NAD+ synthesis is not required since 
enzymatically-inactive WldS still protects. In addition, NAD+ by itself is axonally 
protective and together with WldS is additive in the MPP+ model. Our data 
suggest that NAD+ and WldS act through separate and possibly parallel 
mechanisms to protect DA axons. As MPP+ is thought to impair mitochondrial 
function, these results suggest that WldS might be involved in preserving 
mitochondrial health or maintaining cellular metabolism. 
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2.1  Introduction  
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder in the U.S., affecting 1-2% of people over the age of 55. Characterized 
by loss of dopaminergic neurons in the substantia nigra (SN) [1-2], the cardinal 
motor symptoms of PD include resting tremor, bradykinesia, rigidity, and 
abnormal gait [3-4]. Another characteristic of PD is its late onset and progressive 
nature. Symptoms appear after 50-70% [5-6] of striatal dopamine (DA) has been 
depleted and 30-50% [7-8] of the nigral DA cells have died. Such studies suggest 
that the extent of striatal DA depletion is better correlated with the severity of PD 
symptoms than the loss of DA neurons in the SN [7].  
Data from PD-linked genetic mutations also support the notion that axonal 
pathology and/or dysfunction occurs prior to the loss of DA cell bodies. For 
example, -synuclein pathology is seen in neurites before it is observed in PD-
associated cell bodies [3, 9]. α-synuclein mutants accumulate in the cell soma 
when overexpressed in cortical neurons, suggesting impaired axonal transport as 
well [10]. Moreover, transgenic models expressing the PD-linked mutant gene 
leucine rich repeat kinase 2 (LRRK2) also exhibit pronounced axonal loss and 
pathology prior to cell body loss [11]. In addition, genetic mutations in other PD-
linked genes such as Parkin, an E3 ligase [12], and PINK1 (PTEN-induced 
putative kinase 1 protein) a mitochondrially-targeted kinase, also alter axonal 
transport [13-14]. Collectively, these findings have led to the idea that nigral 
neurons degenerate through a “dying back” axonopathy where degeneration 
starts in the distal axon and proceeds over time towards the cell body.  
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Environmental toxins known to mimic PD such as rotenone and MPP+ also 
disrupt axonal function. These factors not only inhibit mitochondrial Complex I 
activity, but also de-polymerize microtubules leading to axon fragmentation and 
decreased synaptic function [15-17].  Moreover, MPP+ can directly inhibit axon 
transport in the squid axoplasm [18] and DA neurons [19]. Thus, results from PD-
associated environmental and genetic factors support an early, critical role for 
axonal impairment in PD.  
Recent data suggest that the Wallerian degeneration slow fusion protein 
(WldS) can delay axonal degeneration about 10-fold from a wide variety of 
genetic and toxin-inducing stimuli in the peripheral nervous system [20]. WldS 
also blocks axon degeneration in several central nervous system (CNS) models 
of degeneration including animal models of PD [21-22]. For example, we 
previously found that WldS rescues 85% of DA axons for at least 7 days post 
MPTP treatment in vivo [23]. Because no other mutation or drug protects axons 
as robustly as WldS, understanding how the WldS fusion protein is able to prevent 
axon degeneration is the first step towards defining an intervention that would 
leave axons intact.      
WldS is a chimeric protein composed of the first 70 amino acids of the 
ubiquitination factor E4b (Ube4b) followed by an 18-amino acid linker region and 
then the entire coding sequence for nicotinamide mononucleotide 
adenylyltransferase (Nmnat1), a nicotinamide adenine dinucleotide (NAD+) 
synthesizing enzyme [20]. Most studies suggest that catalytically active Nmnat1 
is necessary for axonal protection [24-25], hence, exogenous addition of NAD+ 
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has been reported to delay Wallerian degeneration in response to axotomy in 
dorsal root ganglion (DRG) cells [26]. In Drosophila, however, the picture is more 
complex in that Avery et al. [27] showed that Nmnat enzymatic activity is required 
following axotomy whereas Zhai et al. [28] found that Nmnat does not need its 
catalytic domain to protect axons. In this model [28], as well as in a new study 
demonstrating that Nmnat also protects dendrites [29], Nmnat exhibits a separate 
chaperone-like activity which protects axons and dendrites [28, 30].  
Inasmuch as most studies have been done in peripheral model systems 
and because we have previously shown that WldS protects DA terminal fields 
from MPTP in vivo, we used a dissociated midbrain culture system to determine 
the mechanism of WldS-mediated neurite protection in DA neurons. Here, we 
show that, regardless of its enzymatic activity, the entire WldS sequence is 
needed for the WldS’ neuroprotective phenotype in DA neurons. Our data also 
illustrate that NAD+ has a neuroprotective effect that is different from WldS-
mediated protection. 
 
2.2  Materials and methods 
 
2.2.1  Cell culture and toxin treatment  
For primary midbrain cultures, the ventral mesencephalon was removed 
from embryonic day 14 (E14) murine embryos as previously described [31-32]. 
Wild-type (C57/Bl6) and WldS (C57Bl/OlaHsd-WldS) mice were ordered from 
Harlan (Bichester, UK). SIRT1 knockout mice were obtained from Dr. Christian 
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Sheline (Louisiana State University – Health Science Center, New Orleans, LA). 
Cytoplasmic WldS (Cyto WldS) mice were obtained from Dr. Michael Coleman 
(Babraham Institute, UK). Animals were treated in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. All 
procedures were approved by the Washington University School of Medicine 
animal experimentation committee. Plates were pre-coated overnight with 0.2 
mg/ml poly-D-lysine (Sigma-Aldrich, St. Louis, MO). Cells were plated at a 
density of approximately 125,000 cells/cm2 and maintained in serum-free 
Neurobasal medium (Invitrogen, Carlsbad, CA) supplemented with 1X B27 
supplement (Invitrogen), 0.5 mM L-glutamine (Sigma-Aldrich), and 0.01 µg/ml 
streptomycin plus 100 U penicillin. Half of the culture medium was replaced with 
fresh Neurobasal medium after 5 days in vitro (DIV). Cultures were pretreated 
with 1 mM NAD+, 1 mM NMN, 1 mM nicotinic acid mononucleotide (NaMN), or a 
comparable volume of vehicle 24 hours before toxin treatment. Cultures were 
treated with either 1 M 1-methyl-4-phenylpyridinium (MPP+), the active 
metabolite of MPTP or vehicle on DIV 7. Dorsal root ganglion (DRG) cells were 
obtained from E14 murine embryos as previously described [33]. Cells were 
plated on coverslips precoated with 0.1 mg/ml poly-L-ornithine (Invitrogen) and 
32 µg/ml laminin-1 (Invitrogen) and maintained in DRG media which consisted of 
Eagle Minimal Essential Media (Invitrogen) supplemented with chick embryo 
extract (Invitrogen), 10% fetal calf serum (Invitrogen), 50 ng/ml Nerve Growth 
Factor (Harlan Biosciences, Madison, WI) and 50 U/ml penicillin–50 g/ml 
streptomycin. Half of the culture medium was replaced with fresh DRG medium 
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after DIV 5. After transduction with lentivirus on DIV 2, DRG cultures were 
treated with 0.4 M vincristine or vehicle on DIV 7. NAD+, NMN, NaMN, MPP+, 
and vincristine were all obtained from Sigma-Aldrich.  
 
2.2.2  Lentiviral infection of DA neurons 
The lentiviral expression plasmids FUGW, FCIV-WldS, FCIV-Nmnat1, 
FCIV-Ube4b, FCIV-Nmnat3, FCIV- Nmnat1(W170A), FCIV-cytNmnat1, and 
FCIV-WldS(W258A) were obtained from Dr. Jeff Milbrandt (Washington 
University, Saint Louis). Lentiviruses expressing transgenes were generated by 
the Hope Center for Neurological Disorders Viral Core (Washington University, 
Saint Louis). For infection of DRG and primary midbrain neurons, 50 l lentivirus 
(105 infectious units/l) was added to the well of a 7-mm dish containing 
approximately 70,000 neurons on DIV 2. Transduced primary midbrain and DRG 
neurons were treated with MPP+ and vincristine, respectively, on DIV 7. Viral 
infection and transgene expression was monitored using the GFP reporter via 
fluorescent microscopy.  
 
2.2.3 Immunocytochemistry 
Primary DA cultures and DRGs were plated in 7 mm microwell plates 
(MatTek Corp., Ashland, MA). Cells treated with MPP+ were fixed with 4% 
paraformaldehyde (PFA) in PBS after 48 hours. Cultures were stained with 
sheep polyclonal anti-tyrosine hydroxylase (TH) (Novus Biologicals, Littleton, 
CO) and Cy3 anti-sheep antibodies (Molecular Probes, Carlsbad, CA). 
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Localization of cytoplasmic WldS was confirmed using rabbit WldS (gift of M.P. 
Coleman) and Alexa488 anti-rabbit antibodies (Molecular Probes). TH+ cells and 
neurites were counted using unbiased stereological methods (Stereo 
Investigator, MicroBrightField, Williston, VT). DRG cultures treated with 
vincristine were subsequently stained with mouse acetylated tubulin (Sigma-
Aldrich) and Cy3 α-mouse antibodies (Molecular Probes). Neurites were counted 
as described above. All images were acquired by confocal microscopy (Olympus 
Fluoview 500, Olympus, Center Valley, PA) and processed in ImageJ (NIH). 
 
2.2.4 Western Blotting 
Primary midbrain cultures were plated in 48-well plates and transduced 
with the transgene of interest as described above. Lysates were collected in 
RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% NaDoc, 0.1% SDS, 50 mM 
Tris pH 8.0) with protease inhibitor mixture (Roche, Mannheim, Germany) and 
incubated on ice for 30 minutes.  Insoluble cell debris was removed by 
centrifugation and the protein concentration of each cell lysate was determined 
by Bradford protein assay (BioRad, Hercules, CA). Equal amounts of protein 
were run on SDS-polyacrylamide gels and transferred to polyvinylidene diflouride 
(PVDF) membranes (BioRad). PVDF membranes were probed with either rabbit 
WldS antibody or chicken polyclonal anti-GFP antibody (Aves Labs, Tigard, OR). 
As a control, PVDF membranes were also probed with goat polyclonal anti-
HRP60 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The secondary 
antibodies used were either a HRP-linked rabbit antibody or HRP-linked anti-
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chicken antibody and a HRP-linked anti-goat antibody (Jackson 
Immunoresearch, West Grove, PA). Membranes were developed with enhanced 
chemiluminescence (Amersham Biosciences), imaged with a Storm 
PhosphorImager (Molecular Dynamics) and band intensities were determined 
using ImageQuant software (Amersham Biosciences). 
 
2.2.5 Statistical analysis 
GraphPad Prism software (San Diego, CA) was used for statistical 
analysis. All data was collected from a minimum of three independent 
experiments done in triplicate. The significance of effects between control and 
experimental conditions was determined by a Student t-test or one-way ANOVA 
with Bonferroni Multiple Comparisons tests.   
 
2.3 Results 
 
2.3.1  WldS protects DA cell bodies and neurites from MPP+  
Previously we have shown that DA terminal fields but not cell bodies of 
WldS mice are protected against MPTP injury [23]. To confirm and extend these 
observations in a more tractable system, we utilized dissociated cultures of 
midbrain neurons in which 1-5% of the total cells plated are DA [31]. Results 
show that cultures from WldS mice exhibited significant protection of neurites not 
seen in wild type (WT) cultures after MPP+ treatment (Fig. 2.1A,C). Moreover, DA 
cell death from MPP+ treatment was also attenuated in WldS cultures, unlike 
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those seen in vivo (Fig. 2.1A,B). Thus WldS can effectively protect neurites 
(dendrites and axons) as well as cell bodies from known PD mimetics in vitro.  
 
2.3.2 Cytoplasmic WldS protects cell bodies and neurites against MPP+ 
Recent studies have reported that the localization of WldS influences its 
neuroprotective effect. Beirowski et al. have reported that a cytoplasmic version 
of the WldS protein confers a higher level of protection than the native form of 
WldS [34]. In addition, Milbrandt and colleagues have reported that cytoplasmic 
Nmnat1 and Nmnat3, which is primarily localized in the mitochondria, also confer 
a higher level of protection than Nmnat1 [35-36]. To test whether cytoplasmic 
localization of WldS rescued or changed the level of protection seen with nuclear 
WldS, primary DA neurons were prepared from WT and cyto WldS mice, treated 
with MPP+, and analyzed as described. Results show that cyto WldS mice 
exhibited a similar level of protection of DA cell bodies and neurites as seen in 
WldS mice (Fig 2.2). Therefore, as reported for peripheral model systems, WldS 
does not have to be localized in the nucleus; it can also protect neurites from the 
cytoplasm. 
 
2.3.3 Nmnat1 does not protect against MPP+ toxicity 
Many studies, especially in peripheral model systems, have shown that 
Nmnat1 can at least partially mimic the effects of WldS [24, 37]. To determine 
whether this is true in DA neurons, we transduced primary midbrain cultures from 
WT animals with either GFP, WldS, the 70 amino acid fragment of Ube4b found 
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in WldS, or the entire coding region of Nmnat1 using lentiviral vectors expressing 
GFP [37] (Fig. 2.3). We also tested the effects of Nmnat3, cytoplasmic Nmnat1 
(cyto Nmnat1), and enzymatically inactive Nmnat1 (Nmnat1 (W170A)) [25-26] 
(Fig 2.3A). Western blotting was done to confirm that transductions led to similar 
expression levels in dissociated cultures (Fig. 2.3B-D). Despite equivalent levels 
of transgene expression, only neurites transduced with the entire coding 
sequence of WldS were protected from MPP+ injury (Fig. 2.3F).   
Because many studies have suggested that Nmnat and in particular cyto 
Nmnat or axonally targeted Nmnat can be as effective as WldS in protecting 
axons from mechanical or toxic insults, we used DRG cultures as a positive 
control [38-39]. Consistent with those studies, both WldS and cyto Nmnat rescued 
DRG neurites from the neurotoxin, vincristine, whereas the GFP-only and 
inactive WldS virus did not (Fig 2.4). Taken together, these data confirm previous 
results showing that cyto Nmnat is necessary and sufficient to save DRG 
neurites. In contrast, only WldS but not cyto Nmnat, Nmnat1, or Nmnat3 was able 
to protect DA neurons from the neurotoxic effects of MPP+.  
 
2.3.4 Inactive WldS protects cell bodies and neurites against MPP+  
To corroborate the hypothesis that Nmnat1 does not protect DA neurons 
from MPP+, we transduced dissociated primary midbrain cultures with 
enzymatically inactive WldS (W258A; [37]). In contrast to our own results in DRG 
cultures (Fig. 2.4) as well as results published by others using this same 
construct [37], the inactive WldS plasmid was as effective as NAD+-synthesizing 
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WldS animals in protecting DA cell bodies and neurites against MPP+ injury (Fig. 
2.5). Therefore, the entire WldS chimeric protein, but not its NAD+-synthesizing 
activity, is required for neuroprotection of DA neurons.  
 
2.3.5 NAD+ protects cell bodies and neurites against MPP+  
Previous studies have shown that NAD+ itself can be neuroprotective [37]. 
Although Nmnat1 by itself did not recapitulate the neuroprotective effect of WldS 
on dopaminergic neurons, we tested whether NAD+ or one of its precursors (Fig. 
2.6A) rescued cell bodies or neurites from MPP+ treatment. Therefore, 
dissociated DA WT cultures were pretreated with either 1 mM of NAD+, 
nicotinamide mononucleotide (NMN), or nicotinic acid mononucleotide (NaMN) 
24 hours before MPP+ treatment.  Both NAD+ and NMN but not NaMN protected 
cell bodies and neurites against MPP+ toxicity (Fig. 2.6B,C). These findings 
together with the results showing that catalytically-inactive WldS was able to 
protect DA neurons (Fig. 2.5) but catalytically active Nmnat did not (Fig. 2.3F) 
suggest that different pathways are being invoked in response to MPP+ toxicity. 
 
2.3.6 SIRT1 is not responsible for the NAD+-mediated protection of cell 
bodies and neurites against MPP+ 
Previous studies in DRG neurons have attributed the protective phenotype 
of WldS to its action on the Nmnat1-NAD+-SIRT1 pathway [37]. To test the 
involvement of SIRT1, we prepared dissociated DA cultures from SIRT1 
knockout mice. Following 24 hour pretreatment with 1 mM NAD+ or vehicle 
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control, cultures were exposed to MPP+. Consistent with the notion that NAD+ is 
not acting through SIRT1 but rather through a different mechanism, NAD+ 
protected cell bodies and neurites in SIRT1 knockout cultures from MPP+ toxicity 
(Fig. 2.7).  
 
2.3.7 NAD+ and WldS effects are additive 
The data described above suggest that WldS is acting through a separate 
possibly parallel pathway from that of NAD+ in DA neurons. If so, then adding 
NAD+ to WldS cultures will enhance the neuroprotective phenotype of WldS. To 
see whether the NAD+ effect overlapped with WldS or was additive, dissociated 
DA cultures were prepared from WT and WldS mice and pretreated with and 
without NAD+ as previously described. Both NAD+ and WldS alone exhibited 
similar levels of cell body and neurite protection (Fig. 2.8). However, NAD+ 
together with WldS generated significantly higher levels of protection suggesting 
this is an additive process (Fig. 2.8). To test whether these effects were maximal, 
additional cultures were treated with 5 mM NAD+; no significant differences in 
neuroprotection were observed when compared with the lower dose of 1 mM 
NAD+ (Fig. 2.8D). These findings demonstrate that NAD+ and WldS are additive in 
the MPP+ model suggesting that they are acting through separate and possibly 
parallel neuroprotective mechanisms.  
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2.4 Discussion 
The mechanism(s) by which WldS protects axons is still unclear. 
Peripheral model studies underscore the role of Nmnat and its product, NAD+, in 
protecting axons from various injuries whereas few central nervous system 
studies have been done. Using cellular, molecular and  pharmacological tools, 
the present findings show that the chimeric WldS gene product plays a critical 
role in protecting DA processes, one not dependent upon Nmnat activity. 
Specifically, neither Nmnat, cytoplasmically-targeted Nmnat, nor Nmnat 3 were 
able to prevent toxicity associated with the DA toxin, MPP+ whereas, akin to 
previous reports [26, 37], cyto Nmnat protected DRG axons from known axonal 
toxins. In contrast, WldS, cytoplasmically-expressed WldS, and WldS with an 
inactive Nmnat domain, all significantly protected DA neurites from toxin-
mediated loss. Despite the inability of Nmnat to protect DA processes, NAD+ and 
its precursor, Nmn, were neuroprotective. As WldS and NAD+ were additive in 
this model system, current results suggest that these protectants act through 
separate, possibly parallel pathways. Thus, NAD+ or its derivatives as well as 
WldS and its targets protect DA processes and may aid in the development of 
therapeutics preserving the connections and circuitry important in PD.  
 The role of Nmnat and NAD+ in recapitulating the full effect of WldS has 
been controversial. In vitro studies have shown that overexpression of Nmnat1 
by itself protects axons from many mechanical, genetic or toxin-induced injuries 
[20, 40]. In contrast, transgenic animals expressing nuclear Nmnat1 did not 
replicate the effects of WldS [41-42] whereas cytoplasmically [38] or axonally 
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targeted Nmnat1 [39] were equally if not more effective. Thus, site of action plays 
a role in Nmnat1’s effectiveness [20]. These data together with findings showing 
that the first 16 N-terminal amino acids of the WldS gene product are required for 
full WldS protection [24], possibly by redistributing enough WldS to cytoplasmic or 
axonal compartments, are consistent with the notion that both the N-terminal 
portion of WldS and Nmnat1 are necessary for full axonal protection [20].   
The importance of Nmnat catalytic activity is reflected in several 
mutational studies in which Nmnat’s active sites have been disrupted and 
neuroprotection was lost [24, 27, 37, 42]. Moreover, NAD+ itself and/or some of 
its biosynthetic precursors, protect against axonal degeneration in peripheral 
model systems as well as in experimental autoimmune encephalomyelitis (EAE; 
[26, 43], ischemia [44-45], Alzheimer’s disease [46], and PD [47-49].  In at least 
one study however, addition of NAD+ was not effective [41]. Moreover, 
Drosophila Nmnat (dNmnat) did not require enzymatic activity for axon protection 
against insults such as excitotoxicity, polyglutamine-induced dysfunction, or 
mechanical injury [30] leading to the suggestion that dNmnat may perform a 
chaperone-like function [28]. Indeed, structural studies of various Nmnats have 
revealed characteristic similarities to known chaperones such as UspA and 
Hsp100 [50]. Consistent with this notion, dNmnat was recently shown to function 
as a stress protein in response to heat shock, hypoxia, and the mitochondrial 
Complex I toxin, paraquat [51]. However, in DA neurons, Nmnat1 does not seem 
to function as either an axonal protectant or a chaperone.   
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Studies have indicated that MPP+ can block electron transport by acting at 
the same site as the Complex I inhibitor, rotenone, leading to the production of 
free radical species and a loss of ATP production [52-54]. MPP+ affects other 
processes as well including the rapid release of DA from vesicular stores [55-56]; 
depolymerization of microtubules [16, 57]; induction of autophagy [19, 58], and 
the rapid loss of mitochondrial membrane potential and reduction in 
mitochondrial motility in DA axons [19] . Since many of these effects involve 
mitochondrial function, conceivably the WldS gene product is involved in 
preserving mitochondrial health or maintaining homeostatic control. Recently, 
Barrientos et al. reported that WldS is able to regulate the mitochondrial 
permeability transition pore (PTP) preventing, amongst other things, calcium 
release, ATP loss, oxidative stress and release of proteins involved in axonal 
degeneration [59]. This is consistent with other studies from Wishart et al. 
showing that striatal synaptosomes isolated from WldS versus WT animals 
expressed higher levels of various mitochondrial proteins including the PTP 
protein, VDAC2 [60]. Barrientos et al. suggested that WldS is part of a regulatory 
cascade that also involves JNK activation upstream of PTP opening [59]. 
Although JNK is a known regulator of axon degeneration [61], recently we 
showed that the JNK inhibitor, SP600125, did not prevent MPP+ effects on DA 
mitochondria [19]. Thus diverse, unknown, regulatory steps appear to mediate 
WldS effects in DA axons.  
Given its role as a ubiquitous cofactor, NAD+ influences many cellular 
decisions such as DNA damage repair [62] and transcriptional regulation and 
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differentiation [63]. Earlier studies suggested that increased NAD+ levels led to 
SIRT activation which, in turn, activated a transcription factor that induced genes 
involved in neuroprotection [30, 37]. Although an attractive hypothesis, 
subsequent studies using SIRT1 knock out animals did not support this notion for 
DRG neurons [64], or as in the present study, for DA neurons (Fig 2.8).  
Why are results in DA neurons different than other systems? Because 
many of the studies published have been performed in peripheral model systems 
with dramatically over-expressed protein, there may be neuronal-specific or 
expression level-related effects that might account for the differences. For 
example, WldS has shown protection in several central nervous system models, 
but few have been further tested with only Nmnat1 even in dissociated neuronal 
models. Then too, DA axons may have intrinsic differences that contribute to the 
WldS effect. For instance, DA neurons have fewer [65], smaller and slower 
mitochondria than non-DA neurons [19]. Moreover, DA neurons produce a 
neurotransmitter prone to oxidation [66], exhibit a greater dependence on L-type 
Ca2+ channels with subunits that result in deleterious amounts of intracellular 
calcium and ensuing mitochondrial dysfunction [67], and extend long, thin lightly-
myelinated processes which are selectively vulnerable in PD [68]. These unique 
characteristics in DA neurons may require higher levels and/or different forms of 
a neuroprotective agent in order to be effective. 
In support of our previous in vivo study showing that WldS protects DA 
terminal fields from MPTP [23], the current results demonstrate in dissociated DA 
cultures that the entire WldS sequence is needed for axonal protection, 
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regardless of its NAD+-synthesizing activity. Indeed, NAD+ and WldS act through 
separate, possibly parallel, mechanisms to protect DA axons. As MPP+ is thought 
to impair mitochondrial function, these results suggest that WldS might be 
involved in preserving mitochondrial health or maintaining cellular metabolism. 
Given that Parkinson’s disease is the second most common neurodegenerative 
disease, our findings support the idea that studies expanding therapeutic efforts 
towards maintaining connections as well as saving the cell body will help in 
developing better interventions for PD. 
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Figure 2.1 - Wlds protects DA neurons from MPP+ toxicity. (A) Dissociated 
DA cultures from both WT and Wlds mice were treated with 2 m MPP+ for 48 
hours, and processed for TH immunoreactivity. (B) Quantification of TH+ cell 
bodies and (C) TH+ neurites was done using unbiased stereology. Data are 
normalized to control cultures and denote the mean ± SEM of representative 
determinations made in three separate cultures.  *p<0.01; **p<0.001. 
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Figure 2.2 - Cytoplasmic Wlds protects DA neurons from MPP+ toxicity. (A) 
Dissociated DA cultures from both WT and cyto Wlds mice were co-stained with 
TH and Wlds antibodies to confirm the subcellular localization of Wlds. (B) 
Cultures were treated with 2 m MPP+ for 48 hours prior to fixing and staining. 
(C) Quantification of TH+ cell bodies and (D) TH+ neurites shows that 
cytoplasmic WldS protected both cell bodies and neurites against MPP+. Data are 
normalized to control cultures and denote the mean ± SEM of representative 
determinations made in three separate cultures.  *p<0.05.  
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Figure 2.3 - Nmnat by itself does not protect DA neurons from MPP+ 
toxicity. (A) Diagram of the lentiviral constructs used to transduce WT 
dissociated DA neurons. (B-D) Quantification of the western blots illustrates that 
all the transduced transgenes exhibit similar levels of expression. (E) 
Quantification of TH+ cell bodies and (F) TH+ neurites show that only WldS-
transduced cultures protected neurites against MPP+. Data are normalized to 
control cultures and denote the mean ± SEM of representative determinations 
made in three separate cultures.  *p<0.001. 
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Figure 2.4 - Wlds and cytoplasmic Nmnat1 protect DRG axons from 
vincristine toxicity. (A) DRG cultures from E14 mice transduced with GFP, 
Wlds, cyto Nmnat1, or inactive Wlds were processed for acetylated tubulin 
immunoreactivity 24 hours after vincristine treatment. (B) Quantification of 
neurites shows that both Wlds and cyto Nmnat1 protects DRG neurites from 
vincristine toxicity. Data are normalized to control cultures and denote the mean 
± SEM of representative determinations made in three separate cultures.  
*p<0.05. 
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Figure 2.5 - Inactive Wlds also protects DA neurons from MPP+ toxicity. (A) 
Dissociated DA neurons transduced with GFP or inactive Wlds were treated and 
processed as described. (B) Quantification of TH+ cell bodies and (C) TH+ 
neurites. Data are normalized to control cultures and denote the mean ± SEM of 
representative determinations made in three separate cultures.  *p<0.05.  
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Figure 2.6 - NAD+ protects DA cells and neurites from MPP+ toxicity. (A) 
NAD+ biosynthetic pathway [69]. (B) Dissociated WT DA cultures were pretreated 
with NAD+, NMN, or NaMN 24 hours before addition of 2 m MPP+. 
Quantification of TH+ cell bodies and (C) TH+ neurites show that NAD+ and 
NMN, but not NaMN, protected cells and neurites from MPP+. Data are 
normalized to control cultures and denote the mean ± SEM of representative 
determinations made in three separate cultures. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.7 - NAD+ does not protect DA neurons through the Sirt1 pathway. 
(A) Dissociated midbrain cultures from both WT and Sirt1 KO mice were 
pretreated with NAD+ 24 hours before addition of 2 m MPP+. (B) Quantification 
of TH+ cell bodies and (C) TH+ neurites show that NAD+ protects cells and 
neurites from MPP+ in both WT and Sirt1 KO cultures. Data are normalized to 
control cultures and denote the mean ± SEM of representative determinations 
made in three separate cultures.  *p<0.05. 
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Figure 2.8 - The protective effect of NAD+ and WldS are additive. (A) 
Dissociated midbrain cultures from both WT and WldS mice were pretreated with 
NAD+ 24 hours before addition of 2 m MPP+. (B) Quantification of TH+ cell 
bodies and (C) TH+ neurites show that NAD+ pretreatment was more effective in 
protecting WldS neurites from MPP+ versus untreated WldS cultures. (D) NAD+ 
dose response curve showing that the protection seen with 1 mM NAD+ is 
maximal. Addition of 10 mM NAD+ before MPP+ treatment induced 50% cell 
death in DA neurons (data not shown). Data are normalized to control cultures 
and denote the mean ± SEM of representative determinations made in three 
separate cultures.  *p<0.05; **p<0.001. 
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Chapter 3 
 
 
Wld
S
 but not Nmnat1 protects dopaminergic neurites from 6-OHDA 
neurotoxicity 
 
This manuscript is in preparation for publication 
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Abstract: 
The WldS mouse mutant (“Wallerian degeneration-slow”) delays axonal 
degeneration in a variety of disorders including in vivo models of Parkinson’s 
disease. The mechanisms underlying WldS-mediated axonal protection are 
unclear, although many studies have attributed WldS neuroprotection to the 
NAD+-synthesizing Nmnat1 portion of the fusion protein. We used dissociated 
dopaminergic (DA) cultures to test the hypothesis that catalytically active Nmnat1 
protects DA neurons from the parkinsonian mimetic 6-hydroxydopamine-(6-
OHDA). Using mutant mice and transduced DA neurons, the present study 
demonstrates that the entire WldS protein, but not Nmnat1 or cytoplasmically-
targeted Nmnat1, protects DA axons from 6-OHDA. Additionally, exogenous 
NAD+ was not able to protect DA axons against 6-OHDA. Our data suggest that 
WldS protects DA axons against 6-OHDA independent of its NAD+-synthesizing 
ability. Therefore, WldS may induce a novel gain of function that counteracts the 
effects of 6-OHDA such as the generation of reactive oxygen species and/or 
mitochondrial dysfunction. 
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3.1  Introduction  
Parkinson’s disease (PD) is a late onset and progressive 
neurodegenerative disorder that affects 1-2% of people over the age of 55 in the 
United States. PD is caused by the death of DA neurons in the substantia nigra 
(SN) [1-2] and characterized by the occurrence of resting tremor, bradykinesia, 
rigidity, and abnormal gait in patients [3-4]. Interestingly, symptoms of PD 
manifest after 50-70% [5-6] of striatal dopamine (DA) has been depleted and 30-
50% [7-8] of the nigral DA cells have died. These data are consistent with the 
hypothesis that PD severity correlates better with the extent of striatal DA 
depletion than with the loss of DA neurons in the SN [7].  
PD-linked genetic mutations provide further evidence that axonal 
degeneration occurs prior to DA cell body loss. For example, -synuclein 
inclusions have been reported to be present in neurites prior to the appearance 
of inclusions in neuronal cell bodies [3, 9]. Transgenic models expressing the 
PD-linked mutant gene leucine rich repeat kinase 2 (LRRK2) also exhibit 
decreased DA terminal fields and increased dystrophic processes with abnormal 
axonal swellings [10]. In addition, overexpression of PD-linked LRRK2 mutations 
lead to dramatic reductions in neurite length and branching yet only slight 
changes in cell soma diameter in primary neuronal cultures [11].  
Environmental toxins known to induce Parkinson-like symptoms in animals 
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-
hydroxydopamine (6-OHDA) also exhibit terminal field changes prior to cell body 
loss. For example, MPTP administration in primates leads to marked reductions 
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of DA axons prior to the loss of nigral cell bodies [12]. In mice, Serra and 
colleagues showed that one day after MPTP treatment, striatal DA levels were 
diminished by 60% whereas at this same time point no tyrosine hydroxylase (TH) 
immunoreactive cell bodies were lost in the SN [13]. Other studies using 6-OHDA 
showed that striatal DA levels in the 6-OHDA-lesioned side of rodents were 
decreased by 64% whereas DA was reduced by only 43% in the lesioned SN.  
[14]. Similarly, Ebert et al. demonstrated that four days after 6-OHDA treatment, 
TH levels were significantly reduced in the striatum whereas there was very little 
loss of TH staining in the SN [15]. Finally, studies by Rosenblad et al. showed 
that even one day after 6-OHDA injection, axons already exhibited damaged 
pathology and retraction from the striatum whereas cell death was only observed 
weeks after toxin treatment [16-18].  
Taken together, studies from PD patients as well as evidence from both 
genetic and toxin models of PD support the idea that nigral neurons degenerate 
through a “dying back” axonopathy in which degeneration begins in the distal 
axon and proceeds over weeks or months towards the cell body [19-20]. Hence, 
interventions that can halt or delay the progression of axonal degeneration may 
play an important role in designing therapeutics for PD.  
Mice with the Wallerian degeneration slow (WldS) mutation exhibit 
dramatically delayed axonal degeneration in response to a wide range of genetic 
and toxin-inducing stimuli in both peripheral nervous system (PNS) [21] and 
central nervous system (CNS) models of degeneration [22-25]. In fact, WldS 
provides axon protection in a model of anterograde degeneration induced by 
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injection of 6-OHDA into the medial forebrain bundle [23, 25]. Because no other 
mutation or drug protects axons as robustly as WldS, understanding the 
mechanism by which the WldS fusion protein is able to prevent axon 
degeneration is the first step towards developing an intervention that would leave 
axons intact.      
WldS is a chimeric protein composed of the first 70 amino acids of the 
ubiquitination factor E4b (Ube4b) followed by an 18-amino acid linker region and 
the entire coding sequence for nicotinamide mononucleotide adenylyltransferase 
(Nmnat1), a nicotinamide adenine dinucleotide (NAD+) synthesizing enzyme (Fig. 
3.1A) [21, 26]. Most studies have attributed the neuroprotective effect of WldS to 
the Nmnat1 portion of the protein, since enzymatically inactive WldS or Nmnat1 
does not recapitulate the neuroprotection seen with the native WldS protein in 
certain model systems [27-28].  In support of these studies, exogenous addition 
of NAD+ delays Wallerian degeneration in response to axotomy in dorsal root 
ganglion (DRG) cells [29]. In Drosophila, however, there is evidence both for [36] 
and against [30] the role of Nmnat’s enzymatic activity for neuroprotection. In the 
latter model [30], as well as in a new study demonstrating that Nmnat also 
protects dendrites [31], neuroprotection of axons and dendrites by Nmnat has 
been attributed to a separate chaperone-like activity [30, 32].  
Because it has previously been reported that WldS protects DA terminal 
fields from 6-OHDA in vivo [23], we used a dissociated midbrain culture system 
to determine if Nmnat1 is responsible for the WldS-mediated neurite protection in 
DA neurons. We found that the entire WldS sequence is needed for the WldS’ 
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neuroprotective phenotype against 6-OHDA in DA neurons and present data 
showing that NAD+ cannot protect against 6-OHDA-mediated toxicity.  
 
3.2  Materials and methods:  
 
All of the methods and materials for these set of experiments were 
performed exactly as described for Chapter 2 with the exception that cultures 
were treated with 20 M 6-OHDA with ascorbic acid dissolved in N2-bubbled 
water instead of MPP+ on DIV 7.  
 
3.3 Results 
 
3.3.1 WldS protects DA cell bodies and neurites from 6-OHDA  
DA terminal fields but not cell bodies are protected against 6-OHDA 
treatment in WldS mice [23]. To validate these observations in a more 
manipulable system, we utilized dissociated cultures of midbrain neurons in 
which 1-5% of the total cells plated are DA cells [33]. Cultures from WldS mice 
but not control animals exhibited significant protection of neurites after 6-OHDA 
treatment (Fig. 3.2A,C). In contrast to in vivo results [23], DA cell bodies were 
also protected from 6-OHDA treatment in WldS versus control cultures (Fig. 
3.2A,B), demonstrating that WldS effectively protects neurites (dendrites and 
axons) as well as cell bodies from a known PD mimetic in vitro.  
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3.3.2 Nmnat1 does not protect DA neurons against 6-OHDA toxicity 
Many studies done in PNS model systems have shown that Nmnat1 
completely or partially mimics the effects of the entire fusion protein [28, 34]. To 
determine whether this is true in DA neurons, we transduced primary midbrain 
cultures from wild type (WT) animals with either GFP, the entire WldS coding 
region, the 70 amino acid fragment of Ube4b encoded within the WldS gene, 
Nmnat1, or cytoplasmically-targeted Nmnat1 (cyto Nmnat1) using lentiviral 
vectors expressing GFP [34] (Fig. 3.2). Western blotting was done to confirm that 
transductions led to similar expression levels in dissociated cultures (Fig 2.3). 
Despite equivalent levels of transgene expression, only cell bodies and neurites 
transduced with the entire coding sequence of WldS were protected from 6-
OHDA injury (Fig. 3.2B,C). In addition, although cyto Nmnat1 protects 
dissociated DRG cultures from vincristine treatment in our studies (Fig 2.4) and 
in others [35], it was unable to protect DA neurons from 6-OHDA. These data 
confirm and extend the hypothesis that WldS has a cell type-specific effect in 
given neuronal populations. 
 
3.3.3 NAD+ does not protect DA cell bodies and neurites against 6-OHDA   
It has been previously reported that exogenous application of NAD+ on 
DRGs is neuroprotective [34]. Although transduced Nmnat1 did not rescue DA 
neurons from 6-OHDA treatment (Fig. 3.2), inadequate levels of viral 
transduction may have affected the outcome. Conversely, NAD+ might act in a 
parallel fashion. Consequently, we tested whether exogenous addition of NAD+ 
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or one of its precursors (Fig. 3.3) could rescue cell bodies or neurites from 6-
OHDA treatment. Dissociated primary midbrain WT cultures were pretreated with 
either 1 mM NAD+, nicotinamide mononucleotide (NMN), or nicotinic acid 
mononucleotide (NaMN) 24 hours before addition of the toxin. None of these 
pretreatments protected against 6-OHDA toxicity (Fig. 3.3) suggesting that the 
NAD+-synthesizing activity of WldS is not necessary for its neuroprotective effect 
against 6-OHDA toxicity.  
 
3.4 Discussion 
To date, no consistent hypothesis has emerged on the mechanism(s) 
underlying WldS-mediated axonal protection. PNS model studies have 
emphasized the role of Nmnat in protecting axons from various injuries whereas 
few CNS studies have confirmed this role. Using cellular, molecular and 
pharmacological tools, our study shows that the WldS protein plays a critical role 
in protecting DA processes, but not through its NAD+-synthesizing activity. 
Specifically, Nmnat1, cyto Nmnat1 and NAD+ are all able to protect peripheral 
model systems from toxicity [35,43] whereas none were able to do so in 6-
OHDA-treated dissociated DA cultures. These data support the notion that WldS 
acts in a cell specific manner to rescue neurites from degeneration.  
The importance of Nmnat’s NAD+ synthesizing ability is underscored in 
several studies in which Nmnat’s active sites were disrupted and neuroprotection 
was subsequently lost [28, 34, 36-37]. Moreover, NAD+ itself and/or some of its 
biosynthetic precursors, protect against axonal degeneration in different disease 
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model systems such as autoimmune encephalomyelitis [29, 38], ischemia [39-
40], Alzheimer’s disease [41], and PD [42-44]. In at least one study, addition of 
NAD+ was not effective [45]. In addition, a study in Drosophila found that Nmnat’s 
enzyme activity is not necessary for axon protection following mechanical injury, 
excitotoxic or polyglutamine-induced dysfunction [32], suggesting that dNmnat 
may perform a chaperone-like function [30]. In fact, structural studies of the three 
different Nmnat isoforms have revealed characteristic similarities to known 
chaperones such as UspA and Hsp100 [46]. Consistent with this notion, dNmnat 
was recently shown to function as a stress protein in response to heat shock, 
hypoxia, and paraquat [47]. However, Nmnat1 does not seem to function as 
either an axonal protectant or a chaperone in DA neurons.   
 Our lab has shown that 6-OHDA-oxidized proteins cause ER stress and 
upregulation of the unfolded protein response (UPR), which regulates protein 
folding, protein degradation and protein translation leading to cell death of 
dopaminergic neurons [48]. Activation of UPR-associated proteins such as IRE1α 
was seen in axotomized motoneurons [49], implying a relationship between the 
UPR and axonal degeneration. More recently, Bernstein et al. has found that 6-
OHDA-generated ROS induces DNA damage and causes cell death through a 
p53-dependent mechanism. Cultures from p53 knockout mice exhibited 
protection of both their cell bodies and neurites against 6-OHDA injury [50]. Thus, 
6-OHDA may also cause axonal degeneration through its effect on p53. Finally, 
6-OHDA causes rapid mitochondrial depolarization in both human neuroblastoma 
cell lines (SH-SY5Y) [51-52] and DA neurons [33] demonstrating a direct effect 
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on mitochondrial function. Since mitochondrial dysfunction can trigger axonal 
degeneration [53], loss of neurites following 6-OHDA treatment might be entirely 
due to direct changes in membrane potential. 
 Given the possible means by which 6-OHDA can cause axonal 
degeneration, WldS potentially preserves axons against 6-OHDA injury through 
different mechanisms. For instance, WldS may protect against 6-OHDA toxicity 
by working as an antioxidant. Mouse embryonic fibroblasts from WldS mice show 
protection against paraquat, a PD-linked toxin known to generate ROS [54]. 
Therefore, similar to the case of paraquat, WldS can function as an antioxidant 
that protects DA axons against 6-OHDA-mediated neurite degeneration. As 
described before, Nmnat may also have chaperone activity based on studies in 
Drosophila and on structural similarities to identified chaperone proteins. Even 
though we found that Nmnat1 by itself could not protect DA axons against 6-
OHDA, it is still possible that WldS itself has chaperone activity and that the 70 
amino acid N-terminal fragment of WldS imparts some necessary function in the 
preservation of DA neurons. Although Nmnat1 has been linked to SIRT1 
activation, an NAD+-dependent histone deacetylase, which is in turn linked to p53 
regulation [55], the fact that neither Nmnat nor NAD+ rescued DA neurons from 
6-OHDA toxicity would make this a less likely regulatory pathway. 
 In regards to 6-OHDA’s effect on the mitochondria, a recent study has 
found that WldS is able to regulate the mitochondrial permeability transition pore 
(mPTP) [53], therefore affecting mitochondrial health. This is consistent with 
other studies showing that striatal synaptosomes isolated from WldS versus WT 
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animals expressed higher levels of various mitochondrial proteins including the 
mPTP associated protein, VDAC2 [56]. Therefore, the WldS protein may also 
protect against 6-OHDA-mediated injury by preserving mitochondrial integrity. 
Additional studies are underway to explore these possibilities.   
 In vivo, WldS provided remarkable axon protection in a model of 
anterograde degeneration induced by injection of 6-OHDA into the medial 
forebrain bundle. But surprisingly, WldS did not confer protection against a 
retrograde model of DA axon degeneration by injection of 6-OHDA into the 
striatum [23]. These findings were confirmed by Cheng et al. in transgenic mice 
that express green fluorescent protein using the TH promoter to visualize and 
quantify DA axons following injury [25]. These results identify a definitive, 
fundamental difference between mechanisms of anterograde and retrograde 
degeneration in DA axons. It will be interesting to see whether these findings are 
recapitulated in vitro using our microchamber devices (Chapter 4).  
 In support of previous in vivo work showing that WldS protects DA terminal 
fields from 6-OHDA, our study demonstrates that the entire WldS sequence is 
needed for axonal protection against 6-OHDA-mediated toxicity in dissociated 
DA cultures. We also show that NAD+ by itself is not able to confer protection of 
DA neurons against 6-OHDA. This suggests that the WldS protein may produce a 
novel gain of function that counteracts the effects of 6-OHDA such as the 
generation of ROS, activation of UPR, p53 upregulation, and/or mitochondrial 
dysfunction. Given that PD is the second most common neurodegenerative 
disorder, our findings support the idea that studies expanding therapeutic efforts 
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towards maintaining connections as well as saving the cell body will help in 
developing better interventions for PD. 
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Figure 3.1 - Wlds protects DA neurons from 6-OHDA toxicity. (A) Schematic 
of mouse WldS fusion protein structure. GenBank accession number AAG17285, 
adapted from Coleman (2005). Amino acid residue numbers relative to Ube4b 
and NMNAT1 are shown [57]. (B) Dissociated DA cultures from both WT and 
Wlds mice were treated with 20 m 6-OHDA for 24 hours, and processed for TH 
immunoreactivity. (C) Quantification of TH+ cell bodies and (D) TH+ neurites was 
done using unbiased stereology. Data are normalized to control cultures and 
denote the mean ± SEM of representative determinations made in three separate 
cultures.  *p<0.01; **p<0.001. 
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Figure 3.2 - Nmnat1 by itself does not protect DA neurons from 6-OHDA 
toxicity. (A) Dissociated DA cultures from WT mice were transduced with 
transgenes for GFP, WldS, 70AA-Ube4b, Nmnat1, and cyto Nmnat1 at DIV2 then  
treated at DIV7 with 20 m 6-OHDA for 24 hours, and processed for TH 
immunoreactivity. (B) Quantification of TH+ cell bodies and (C) TH+ neurites 
show that only WldS-transduced cultures protected cells and neurites against 6-
OHDA. Data are normalized to control cultures and denote the mean ± SEM of 
representative determinations made in three separate cultures.  *p<0.001. 
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Figure 3.3 - NAD+ does not protect DA cells and neurites from 6-OHDA 
toxicity. (A) Dissociated WT DA cultures were pretreated with NAD+, Nmn, or 
Namn 24 hours before addition of 20 m 6-OHDA. (B) Quantification of TH+ cell 
bodies and (C) TH+ neurites show that none of the pretreatments protected cells 
and neurites from 6-OHDA. Data are normalized to control cultures and denote 
the mean ± SEM of representative determinations made in three separate 
cultures.    
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Abstract 
Impaired axonal transport may play a key role in Parkinson’s disease. To 
test this notion, a microchamber system was adapted to segregate axons from 
cell bodies using green fluorescent protein-labeled mouse dopamine (DA) 
neurons. Transport was examined in axons challenged with the DA neurotoxin, 
1-methyl-4-phenylpyridinium ion (MPP+). MPP+ rapidly reduced overall 
mitochondrial motility in DA axons; among motile mitochondria, anterograde 
transport was slower yet retrograde transport was increased. Transport effects 
were specific for DA mitochondria, which were smaller and transported more 
slowly than their non-DA counterparts. MPP+ did not affect synaptophysin-tagged 
vesicles or any other measureable moving particle. Toxin effects on DA 
mitochondria were not dependent upon ATP, calcium, free radical species, JNK, 
or caspase3/PKC pathways but were completely blocked by the thiol-anti-oxidant 
N-acetyl-cysteine or membrane-permeable glutathione. Since these drugs also 
rescued processes from degeneration, these findings emphasize the need to 
develop therapeutics aimed at axons as well as cell bodies to preserve “normal” 
circuitry and function as long as possible.  
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4.1  Introduction 
 Impaired axonal transport plays an important role in a variety of 
neurodegenerative disorders, including Parkinson disease (PD) [1]. Postmortem 
studies on PD patients show widespread axonal pathology that appears to 
precede the loss of cell bodies [2], supporting the notion that nigral neurons 
degenerate through a “dying back” axonopathy [3]. Animal models of PD-linked 
genes also point to axonal impairment as being a critical factor. For example, 
transgenic mice expressing the PD-linked R1441G LRRK2 mutation exhibit 
decreased dopamine (DA) terminal fields together with increased dystrophic 
processes and abnormal axonal swellings, findings consistent with DA 
axonopathy [4]. Reduced axonal transport is also seen with -synuclein mutants, 
which accumulate in the cell soma when overexpressed in cortical neurons [5]. 
Moreover, vesicle-associated -synuclein binds to microtubule motor proteins 
like kinesin and dynein, underscoring a potential role in microtubule-dependent 
axonal transport [6]. In addition, genetic mutations in Parkin, an E3 ligase, and 
PINK1, a mitochondrially targeted kinase, lead to impaired mitochondrial 
dynamics, resulting in altered transport and distribution of mitochondria as well 
as loss of synaptic function [7]. PINK1 can also form a complex with Miro and 
Milton [8], proteins known to recruit kinesin to the mitochondria and promote 
motility along microtubule tracks [9]. Thus, these PD-linked mutations are 
consistent with the idea that axonal dysfunction plays an early and significant role 
in the disorder. Environmental toxins mimicking PD such as N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) or its active derivative, 1-methyl-4-
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phenylpyridinium ion (MPP+), also disrupt axonal function. MPTP-treated 
monkeys [10] or mice [11] first lose DA terminal fields and then exhibit cell body 
loss. Moreover, Wallerian degeneration slow (WldS) mutant mice rescue DA 
projections in MPTP-treated animals but not cell bodies, emphasizing the 
independence of cell body function versus axon specialization [12]. In addition, 
MPP+ can directly inhibit axon transport in the squid axoplasm [13]. Although the 
mechanisms underlying the latter response are unclear, in vertebrate models 
MPP+ depolymerizes microtubules, leading to axon fragmentation and decreased 
synaptic function [14-15]. Difficulty in assessing real-time changes in DA axons 
has precluded testing models of structural or trafficking impairment. Although 
much can be learned from the squid giant axon, this system as well as studies in 
vertebrate peripheral, cortical, or other non-DA cell types [15], may be 
unrepresentative of a bona fide DA neuron. Recently, we have adapted a 
microchamber system in which axons are segregated to one side, leaving cell 
bodies and dendrites on the other. When used with GFP-labeled DA neurons 
derived from genetically engineered mice, DA axons can be examined using 
targeted fluorescent markers and time lapse imaging. Using these chambers, 
here we show that MPP+ specifically decreases mitochondrial movement in DA 
axons. We also explore potential mechanisms underlying the effect of MPP+ on 
mitochondrial transport in DA axons. 
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4.2  Materials and Methods 
 
4.2.1  Cell culture and microchamber devices  
Murine mesencephalic cultures were prepared, treated with toxin for 
indicated time periods, then fixed and stained for tyrosine hydroxylase (TH) as 
described previously [16]. TH-positive cell bodies and neurites were counted 
using Stereo Investigator (MBF Bioscience). DA/GFP cultures were prepared 
from embryonic day 14 Tg(TH-EGFP)DJ76GSAT transgenic mice (Gene 
Expression Nervous System Atlas, National Institutes of Health, Bethesda, MD). 
Typically DA/GFP males were mated with wild-type females. Brains isolated from 
the resulting embryos were screened for GFP fluorescence before midbrain 
dissection. GFP-positive tissue was pooled and plated. Microchamber devices 
were modified from Ivins et al. [17]. Briefly, 20mmglass bottom culture dishes 
(MatTek) were coated with 100 g/ml Matrigel (BD Bioscience), rinsed with 
DMEM/F-12, and dried. A polytetrafluoroethylene Teflon tubing [17 (outside 
diameter) x 13 (inside diameter) x 2 (wall thickness) x 5 mm (length)] was cut in 
half and attached to the bottom of the dish using sterile vacuum grease. A 
rectangular glass coverslip (9 x 18 mm) was sandwiched between both pieces of 
Teflon and sealed in place with a Matrigel/collagen complex (1 mg/ml collagen 
type I, 3 mg/ml Matrigel, DMEM). Isolated neurons (250,000 cells/cm 2) were 
plated on one side of the chamber in DMEM/F-12, 5% FBS, supplemented with 
B-27 (Invitrogen) and penicillin/ streptomycin. Axonal chambers were 
supplemented with 300 g/ml NetrinI (R&D Systems) to direct axonal outgrowth 
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under the coverslip. Transport was assessed between days in vitro (DIV) 12 and 
14. 
 
4.2.2 Determination of cell viability  
To determine DA cell viability following MPP+ treatment both in cell bodies 
and neurites, mesencephalic cultures were processed for TH immunoreactivity 
and counted using Stereo Investigator (MBF Bioscience). Briefly, 50 fields were 
assayed per dish leading to the quantification of 200–300 TH neurons and 2000–
5000 neurites/dish. Experiments were repeated 3–5 times using cultures isolated 
from independent dissections. 
 
4.2.3 Quantification of tubulin 
The tubulin-mCherry construct was prepared by replacing the EGFP 
sequence of pEGFP-tubulin (Invitrogen) with mCherry (Dr. Mike Nonet, 
Washington University, St. Louis, MO). Neurons were transfected using 
Lipofectamine 2000 (Invitrogen) at DIV5-6 and imaged 1 d later. Live images 
were taken at 1, 3, 6, and 24 h after MPP+ treatment. Tubulin integrity was also 
measured by immunostaining with antibodies against tyrosine hydroxylase (Pel-
Freez Biologicals) and acetylated tubulin (AcTub; Sigma) on the axonal side of 
microchamber devices. TH-positive axons with at least three AcTub breaks per 
40 m of axon were considered damaged and calculated as the percentage total 
of all TH-positive axons. 
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4.2.4 Autophagy 
Cells were transfected with a GFP-tagged LC3 expression vector (kindly 
provided by Dr. Chris Weihl, Washington University) at DIV5-6 as previously 
reported(Kumaet al., 2007). A day later, cells were treated with 2 M MPP+ for 
the indicated time, fixed, and immunostained with a rabbit anti-TH antibody (Pel-
Freez Biologicals). Cy3-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories) were used for visualization. TH-positive neurons 
with LC3-GFP granules were counted using Stereo Investigator (MBF 
Bioscience). 
 
4.2.5  Optical imaging 
At DIV12–14, mitochondria on the axonal chamber side were labeled with 
25 nM MitoTracker Red (MTR; Invitrogen). Plasmids containing mitochondrially 
targeted Dendra2 and synaptophysin fused in frame with cerulean (Syn-Cer) 
were provided by Evrogen and Dr. Rachel Wong (University of Washington, 
Seattle, WA), respectively. Subsequently, mitochondrially targeted Dendra2 and 
Syn-Cer were inserted into the FUGW lentiviral expression vector provided by Dr. 
Jeffrey Milbrandt (Washington University). Lentiviral preparations were generated 
using HEK 293T cells as described previously (Araki et al., 2004). DA/GFP 
cultures were inoculated with virus at DIV2 for 4–6 h and imaged at DIV12–13. 
Images were taken using a Zeiss LSM510 Meta NLO Multiphoton System (Carl 
Zeiss) on Axiovert 200M inverted microscope with 40x water objective [C-
Apochromat 40x/1.2W Corr.1.2 numerical aperture, collar correction (0.14–0.18)] 
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equipped with a 5% CO2/37°C controlled chamber. Filter sets used for 
visualizing a given fluorescent marker included 488 nm argon laser and 505 long 
pass emission filter (GFP and Dendra2), 543 nm HeNe laser and 560 long pass 
emission filter [MTR, tetramethylrhodamine ethyl ester (TMRE), or tubulin-
mCherry], and 458 nm argon laser and 466–514 meta emission filter (Syn-Cer). 
Sixty images at 5 sec intervals were acquired before addition of toxin and then 
again 30 min after 2 M MPP+ treatment. 
 
4.2.6 Image analysis 
Kymographs were created using ImageJ/Multiple Kymograph (NIH, 
Bethesda, MD). In all cases, direction was determined by identifying the axonal 
terminal from tile scanned images. To calculate particle speed in each direction, 
the following approach was adopted. Diagonal lines were drawn for each moving 
particle on a kymograph. Angle and length information were collected for each 
particle’s diagonal line. Distance and time were calculated using the following 
equations in which 112.5 m was the frame length, 512 the pixel size, and 5 sec 
the interval of time-lapse images: 
 
Distance (m) = (112.5 * {Length * COS[RADIANS(Angle)]})/ 512   (1) 
Time (s) = 5 * {-Length * SIN[RADIANS(Angle)]}     (2) 
 
Total numbers of particles were obtained using particle analysis with a threshold 
image. Only particles moving a minimum of 5 m in length for at least 15 sec 
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within the imaging time were counted. Particle size was assessed using 
ImageJ/Particle analysis. Anterograde movements are expressed as positive 
integers whereas retrograde movement is expressed by negative integers. 
 
4.2.7  [3H]Dopamine release 
DA release on the microchamber devices was measured as described 
previously [18](Lotharius and O’Malley, 2000). Briefly, cells were loaded in both 
somal and axonal sides with 2.4 Ci/ml [3H]DA/Krebs–Ringer solution for 20 min 
at 37°C and washed 3 times for 3 min. Radioactive counts from a wash sample 
were measured using a Beckman scintillation counter and used as a control for 
basal levels of [3H]DA release. Cells were then treated with MPP+ for 10 min, and 
the amount of [3H]DA released during this time period was counted. Cultures 
were then washed extensively and maintained in [3H]DA-free Krebs–Ringer 
solution. Following medium collection, cells were lysed in 0.1 N perchloric acid by 
freeze thawing, and residual, intracellular [3H]DA was measured. Total counts 
and percentages were calculated. 
 
4.2.8 Mitochondrial membrane potential and size 
Cells were loaded with either 50 nM TMRE (Invitrogen) or MTR for 15 min 
and medium was subsequently added for a final concentration of 25 nM. 
Mitochondrial potential was assessed based on changes in TMRE fluorescence 
before and after toxin treatment as described by Ward [19]. The cross area of 
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axonal mitochondria was estimated by MTR fluorescence using ImageJ/ particle 
analysis. 
 
4.2.9 Statistical analysis 
One-way ANOVA and unpaired two-tailed Student’s t test were used for 
statistical analysis (SAS, GraphPad Software). 
 
4.3  Results 
 
4.3.1 MPP+ causes neuritic degeneration and autophagy before cell body 
loss 
Because MPP+ serves as a substrate for the plasma membrane DA 
transporter [20], its toxic effects are highly selective for DA neurons versus the 
non-DA interneurons that predominate dissociated mesencephalic cultures. 
Consistent with in vivo results showing that loss of DA terminal fields occurs 
earlier and is more pronounced than cell body loss [10-11], MPP+ leads to a 
significant loss of neurites in dissociated DA cultures before cell bodies are 
affected. As early as 12 hours post-MPP+ treatment, neurite loss was apparent 
(Fig. 4.1A). It should be noted that most of the “neurites” measured here have 
morphological features of proximal dendrites in that they exhibit a wide diameter 
that tapers away from the cell body. When compartmentalized axons (Fig. 
4.2A,B) were assessed for fragmentation at 12 hours, significantly more 
fragmentation was observed (70.3 + 8.9% nontreated axon control versus 50.4 + 
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8.4% nontreated dendritic control, p  0.05). These data suggest that axons are 
more vulnerable than dendrites in the presence of MPP+. In contrast, TH-positive 
cell bodies were not significantly reduced until 24 hours later and then by only 
~40% (Fig. 4.1B). Because DA uptake sites vary among DA neurons from the 
substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) [20] 
and that the described dissociated DA cultures would contain neurons from both 
populations, some variability among MPP+ effects is to be expected. Thus, a 40% 
death level might represent all of the DA SNpc neurons, yet only a small fraction 
of DA neurons arising from the VTA. 
Since MPP+ is thought to depolymerize microtubules [14](Cappelletti et al., 
2005), we stained DA/GFP cultures with antibodies directed against acetylated -
tubulin, a marker of stable microtubules, and examined DA axons for the 
presence of beading and/or fragmentation. “Beading” was first observed by 6 h 
(Fig. 4.1C, arrowheads), although no significant fragmentation was observed at 
this time point (Fig. 4.1D). To confirm and extend this result, the integrity of 
tubulin was also assessed by introducing a tubulin-mCherry construct into 
dissociated DA cultures. The mCherry-positive axons were examined for breaks 
in DA (GFP+) and non-DA (GFP-) processes at various time points following 
MPP+ treatment. Consistent with MPP+ effects on acetylated -tubulin, significant 
axonal disintegration in DA neurons was not seen until 6 hours posttreatment, 
which exceeded 80% by 24 hours (Fig. 4.1E,F). Together, these data indicate 
that MPP+ affects one important component of axonal structure, namely the 
microtubule tracks, 12–18 hours before significant cell body loss is observed.  
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MPP+ has been shown to induce autophagy, a catabolic system to 
degrade and recycle damaged proteins and/or organelles [21] within 24 hours in 
DA neurons [22]. To determine whether the disruption of microtubule tracks 
preceded the induction of autophagic markers such as LC3 (microtubule-
associated protein 1, light chain 3; also known as ATG8) [23], we transfected an 
LC3-GFP clone into DA cultures and measured the appearance of autophagic 
granules. Under normal conditions, LC3-GFP fluorescence exhibits a diffuse 
cytoplasmic distribution (Fig. 4.1G). As early as 3 hours after toxin treatment, 
LC3 takes on a punctuated appearance as it localizes to the inner membrane of 
forming autophagosomes (Fig. 4.1G,H). This observation confirms and 
accelerates the timeframe reported by Zhu et al. [22]. Moreover, these results 
suggest that even before damaged microtubules are apparent, other toxin-
induced molecular events induce hallmarks of autophagy. 
 
4.3.2 MPP+ disrupts mitochondrial axonal transport 
MPP+ also inhibits complex I, leading to mitochondrial dysfunction [24]. To 
analyze mitochondrial movement, size, and membrane potential (m) in DA 
processes, we initially used a microfluidic strategy [25]. However, DA neurons 
attached poorly and were highly susceptible to shear stress resulting from 
plating, media changes, and/or toxin addition. Using a simplified chamber design 
[17], we established compartmented cultures such that: (1) axons were 
segregated from cell bodies and dendrites; (2) transport direction was easily 
discerned, imaged, and quantified; and (3) cell bodies or axons could be 
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independently exposed to drugs, toxins, DNA, etc. (Fig. 4.2A). When we used 
dissociated cultures from DA/GFP mice, DA axon terminals could be identified 
via GFP fluorescence (Fig. 4.2B). Immunostaining with the dendritic marker 
MAP2 (microtubule-associated protein 2) or axon-preferring tau verified that 
processes that grew under the glass coverslip were axons, not dendrites (Fig. 
4.2C). To avoid overlapping fluorescent emissions in analyzing mitochondrial 
movement, we considered several approaches. These included: (1) lipid-based 
transfections with mitochondrially targeted DsRed2 (mtDsRed2) and/or the 
photoactivatable fluorescent protein Dendra2 (mtDendra2); (2) transductions with 
the same constructs packaged as lentiviral particles; and (3) mitochondrial dyes 
such as MTR and TMRE. In the first scenario, finding fluorescently labeled 
mitochondria in DA/GFP axons for live imaging is hampered by the low numbers 
of DA neurons typically isolated (2–5% of the total) and low transfection 
efficiencies in these cultures (5%). The second scenario, lentiviral transduction of 
fluorescent proteins targeted to the mitochondria (mtDsRed2; mtDendra2), was 
more efficient and, at least with mtDendra2, provided the option of following 
particles after photoconversion. Caveats associated with the third scenario 
include the notion that mitochondrial dyes might interfere with mobility [26-27]. 
Thus we started these studies using a targeted mtDendra2 lentivirus. Although 
Dendra normally emits at the same wavelength as GFP before excitation, it is 
easy to discern mitochondrially targeted Dendra in DA axons because the latter 
typically exhibit a smooth, homogenous pattern of GFP expression distinct from 
the tubulovesicular appearance of mtDendra2 (Fig. 4.2D). That these structures 
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represent mitochondria can be shown by colocalization with the fluorescent 
lipophilic cation TMRE, which rapidly accumulates in mitochondria (Fig. 4.2D). 
Unfortunately, in our system mtDendra2 did not photoconvert with the efficiency 
or at the wavelength originally claimed [28]; nonetheless, analysis of 
nonconverted mtDendra2 particles showed that MPP+ decreased total numbers 
of moving mitochondria (Fig. 4.2E,F). Moreover, MPP+ treatment decreased 
mitochondrial speeds in the anterograde direction but increased them in the 
retrograde direction (Fig. 4.2G). 
Despite the usefulness of mtDendra2, the small number of DA neurons 
and variability associated with transduction still made acquiring sufficient data in 
multiple experimental paradigms logistically challenging. In contrast, 
mitochondrial dyes have the benefit of labeling all mitochondria within a chamber, 
ensuring adequate numbers for analysis despite potential limitations such as 
diffusion of fluorescence, quenching, and interference with bioenergetic states 
[26]. At least some of these limitations can be overcome when low 
concentrations (50 nM) of MitoTrackers such as MTR are used [26, 29-31]. In our 
studies, excellent loading and labeling of mitochondria was achieved using even 
lower concentrations of MTR (25 nM). At this concentration, MTR labeled exactly 
the same structures that TMRE did (data not shown). More importantly, when an 
identical experimental protocol was used to measure MTR-labeled mitochondria, 
essentially the same results as those for mtDendra2 were produced (Fig. 4.3). In 
either case, we observed that like other neurons [32], >70% of all axonal 
mitochondria were stationary [32]. Of those mitochondria that were moving, over 
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50% had stopped after only 30 min of MPP+ treatment (Figs. 4.2F, 4.3B). 
Moreover, the number of moving mitochondria was reduced in either the 
anterograde or retrograde direction (Figs. 4.2G, 4.3C). In agreement with 
previously published values [33], motile DA mitochondria moved with an average 
speed of 0.32 m/s in the anterograde direction, whereas a slower rate was 
observed in the retrograde direction (0.26 m/s) (Figs. 4.2G; 4.3C). Following 
MPP+ treatment these rates were reversed: anterograde velocity was reduced 
whereas retrograde speed was accelerated (Figs. 4.2G, 4.3C). Thus, MPP+ 
rapidly affects both the fraction of motile DA mitochondria and the speed at which 
they travel. These data suggest that in this cell system and at this concentration 
MTR is a reliable measure of mitochondrial mobility. Importantly, using two 
different approaches essentially the same results were observed: MPP+ rapidly 
reduced overall mitochondrial motility in DA axons; among motile mitochondria, 
anterograde transport was slower yet retrograde transport was increased. 
  
4.3.3 MPP+ does not affect vesicular transport 
To determine whether MPP+ affects all cargo movement or just that of 
mitochondria, DA/GFP cultures in microchamber devices were transduced with a 
lentivirus expressing Syn-Cer (Fig. 4.4A,B). As shown by others [34], the 
synaptophysin sequence targets small, rapidly moving particles that do not 
colocalize with MTR (Fig. 4.4A). Despite inhibiting mitochondrial movement 
within 30 min, MPP+ did not affect the number or speed of synaptophysin-tagged 
particles moving in either direction (Fig. 4.3B–D). Since numerous studies have 
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also shown that MPP+ is taken up into vesicular compartments where it rapidly 
(10 min) leads to the displacement of DA [18], which was reproduced in our 
microchamber devices (Fig. 4.5), these results emphasize that the presence of a 
neurotransmitter is not a requirement for transport. As synaptophysin labels only 
synaptic vesicles, we also examined all moving particles using transmitted light 
images. After subtracting out mitochondria from MTR-colabeled axons, the 
remaining particles showed no significant difference in movement following toxin 
treatment (data not shown). These data underscore the specificity of the MPP+ 
effect on mitochondria versus general axonal cargos and also rule out damaged 
microtubules as a contributing factor in decreased mitochondrial motility. 
 
4.3.4 MPP+ rapidly depolarizes axonal mitochondria 
MPP+ inhibition of complex I leads to ROS, loss of m, and eventually 
loss of ATP [35]. Previously we showed that MPP+-induced ROS changes 
occurred within 15 min in DA cell bodies using dihydrorhodamine and 
dihydroethidium [16, 36]. Although we could confirm our cell body results, we 
could not quantitate ROS changes in DA axons with these reagents (data not 
shown). To determine whether m was altered over the same time period that 
movement was reduced, segregated DA/GFP axons were labeled with the 
sensitive m indicator TMRE before acquiring baseline images. After 30 min of 
toxin treatment, m was significantly reduced in DA (79.8 + 7.23% decrease in 
TMRE fluorescence) (Fig. 4.6B) but not non-DA axonal mitochondria (< 12.9 + 
7.34% TMRE fluorescent decrease) (Fig. 4.6B), highlighting the DA-specific 
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nature of the MPP+ effects. Because bioenergetic declines are thought to shift 
fusion/fission dynamics toward fission, resulting in smaller mitochondria [37], we 
measured mitochondrial size. Although TMRE-labeled mitochondria appeared to 
undergo a decrease in size (Fig. 4.6A), this was due to the loss of TMRE 
fluorescence since MPP+ treatment did not decrease the size of MTR-labeled 
axonal mitochondria (Fig. 4.6C). Thus, MPP+ rapidly depolarized DA 
mitochondria but did not reduce their size, at least in the time frame tested. 
Collectively, these results are consistent with recent work in hippocampal 
neurons showing that depolarized mitochondria travel more rapidly in a 
retrograde direction [38]. 
 
4.3.5 Thiol-based reagents rescue disrupted transport, neurites, and cells 
What are the underlying mechanisms associated with MPP+-mediated 
alterations in transport? Conceivably, MPP+-compromised mitochondria block 
transport due to the ATP dependency of the molecular motors. In the squid 
axoplasm preparation, however, MPP+ effects on fast axonal transport were 
independent of ATP production. Rather, MPP+ treatment led to axonal activation 
of caspase-3, which in turn cleaved PKC into its catalytically active fragment 
[13]. Like the squid preparation, increasing ATP levels in bona fide DA axons via 
glucose preincubation (ATP levels increased from 3.93 + 0.20 x 10-12 to 4.88 
 + 0.11 x 10-12 mole/g of protein, p-value = 0.002) did not rescue MPP+ 
effects on mitochondrial motility (Table 4.1). One caveat to this finding is that 
there are no methodologies to measure ATP levels in situ. Thus, we cannot rule 
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out the possibility that regional variations in ATP levels might underlie the loss of 
mitochondrial movement. Unlike the invertebrate preparation, neither the PKC 
(Go¨6976) nor the caspase inhibitor, Csp3I-II, blocked MPP+ effects in DA axons 
(Table 4.1) although both inhibitors significantly blocked 6-OHDA-induced DA cell 
death (Go¨6976: 45.94 + 11.48% and Csp3I-II: 50.70 + 11.58% protection). We 
also tested whether Ca2+ chelators would affect mitochondrial transport since 
Ca2+ plays a role in axonal loss [39] and is also implicated in DA 
neurodegeneration [40]. Neither EGTA nor BAPTA-AM prevented MPP+-
disrupted mitochondrial transport at concentrations showing intracellular Ca2+ 
changes in axons using Oregon Green (data not shown). Because axonal injury 
induces activation of the c-Jun N-terminal kinase (JNK) family in the peripheral 
nervous system [41], we examined whether the general JNK inhibitor SP600125 
could rescue toxin-blocked mitochondrial motility in segregated DA axons. 
SP600125 did not affect mitochondrial trafficking (Table 4.1) nor did it prevent 
MPP+-mediated DA cell death at a concentration that was effective for blocking t-
butylhydroperoxide induced DA cell death (64.08 + 2.18% protection). Given that 
MPP+ generates ROS via inhibition of complex I or via release of vesicular DA 
followed by its cytoplasmic oxidation [16, 42], we tested N acetylcysteine (NAC; 
precursor of glutathione), Mn(III)tetrakis(4-benzoic acid) porphyrin (MnTBAP, a 
superoxide dismutase mimetic), and glutathione monoethyl ester (GSHEE; 
membrane-permeable GSH) as axonal protectants. Remarkably, pretreatment 
with the redox-sensitive neuroprotectants NAC and GSHEE completely rescued 
MPP+-induced changes in numbers of motile mitochondria, whereas the anti-
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oxidant, MnTBAP was ineffective at a concentration of 100 M (Table 4.1). 
Moreover, NAC pretreatment not only rescued mitochondrial motility but also 
MPP+-induced neurite and cell body loss (Fig. 4.7). Thus, NAC or similar drugs 
can potentially be useful therapeutic tools. Although these differences may 
simply reflect extruded axoplasm responses versus an intact axon, they may also 
reflect clear differences between vertebrate and invertebrate mitochondrial 
trafficking systems and indicate that redox equilibria may play a critical role in at 
least the mammalian processes. 
 
4.3.6 DA mitochondria are smaller and slower than non-DA mitochondria 
Recent studies show that nigral DA neurons have lower numbers of 
mitochondria in their cell bodies and dendrites than non-DA neurons [43]. To 
determine whether differences exist in organelle size or movement between DA 
and non-DA axons, we measured various critical attributes of axonal 
mitochondria and synaptophysin-tagged vesicles (Table 4.2). Consistent with the 
in vivo study [43], DA mitochondria are about half the size of non-DA 
mitochondria and are transported almost three times slower. Although the density 
of mitochondria along the axon is the same, there are fewer moving mitochondria 
in DA versus non-DA axons. Mitochondrial membrane potential is the same. 
Similarly, the number of moving vesicles per unit length axon is reduced in DA 
versus non-DA axons, but their speed is not (Table 4.2). No difference was found 
in other general moving particles. Importantly, non DA mitochondria were not 
affected by MPP+ in terms of size, mobility, or speed (Table 4.3). Given that 
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these data were acquired from the same experiments in which DA axons were 
analyzed, they serve as useful internal controls showing that the loss of signal or 
change in parameter is not due to bleaching caused by imaging or other non-
specific effects. Together, these data suggest that DA axons may be more 
susceptible to dysfunction than non-DA axons due to innate differences in axonal 
mitochondrial characteristics. 
 
4.4 Discussion 
Mounting evidence suggests that axonal dysfunction precedes the death 
of cell bodies in many neurodegenerative disorders, especially PD. The present 
study uses cellular, optical, and pharmacological techniques to provide new 
insights into the biological changes underlying toxin-mediated DA axonal 
impairment. Results demonstrate: (1) that the PD-mimetic MPP+ affects DA 
neuritic processes and microtubule tracks 12–18 hours before cell bodies appear 
altered, and neuritic autophagic puncta are visible by 3 hours; (2) MPP+ halts 
mitochondrial trafficking in DA but not non-DA axons within 30 min, an event 
which precedes autophagy and loss of microtubules; (3) remaining motile 
mitochondria exhibit decreased anterograde movement but increased retrograde 
trafficking; (4) MPP+ effects are specific for mitochondria, as synaptophysin 
tagged vesicles and other detectable moving particles continue normal 
movements in either direction; (5) decreased mitochondrial trafficking is 
accompanied by a loss of m; (6) loss of mitochondrial movement is not 
associated with ATP loss but rather redox changes; (7) DA mitochondria are 
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smaller and slower than non-DA organelles, suggesting cell type-specific 
differences exist for axonal mitochondria. 
Although widely used as an animal model of PD, the mechanism by which 
MPP+ kills DA neurons remains equivocal. Previously we have shown that MPP+ 
induces a protein synthesis-dependent yet caspase-independent cell death in DA 
neurons that is partially mediated by ROS [16]. In those studies and this one, DA 
cell bodies die over a period of 48 hours following toxin treatment, although early 
loss of neurites is consistently observed [16] (Fig. 4.1). Increased free radical 
species such as mitochondrial superoxide have been proposed as an important 
mechanism underlying the neurotoxicity of MPP+ [44]. Previously, however, we 
have shown that MPP+-induced ROS are primarily derived from toxin-released 
vesicular DA [18] (Fig. 4.5). Since redistributed, cytoplasmic DA is thought to 
form a number of oxidized toxic metabolites, including DA quinones [45], it is 
perhaps not surprising that MnTBAP, a cell permeable SOD mimetic, did not 
show a protective effect. Conceivably, other types of ROS, including hydroxyl 
radicals and/or nitric oxide [44, 46-47], might also play a role in MPP+-mediated 
neurotoxicity. What role, if any, these factors play in axonal transport awaits 
future study. 
Recently, Cartelli et al. [15] also reported that MPP+ affects mitochondrial 
trafficking in the pheochromocytoma cell line PC12. In this study, however, MPP+ 
led to microtubule impairment before transport dysfunction. In contrast, the 
present findings show that mitochondrial dysfunction (30 min) (Figs. 4.2, 4.3, 4.6) 
precedes microtubule fragmentation in DA axons (Fig. 4.1). Although microtubule 
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polymerization is a GTP dependent process [48], it is also controlled by ATP 
dependent pathways. For example, the energy-sensing AMP activated protein 
kinase is required for microtubule stabilization [49]. Conceivably, MPP+-mediated 
energy deprivation over the course of 6 h may underlie microtubule 
fragmentation (Fig. 4.1). 
A direct effect of MPP+ on axonal transport was first seen in the isolated 
squid axoplasm [13]. Despite the evolutionary distance between the squid and 
mouse, in both cases MPP+ decreased anterograde trafficking while increasing 
retrograde movement. However, in the squid axoplasm, MPP+ affected all 
organelles and vesicles moving via fast axonal transport, whereas in bona fide 
DA neurons, toxin-mediated effects were specific for mitochondria. Although 
model preparations such as the squid axoplasm and/or the noradrenergic 
peripheral tumor cell line can yield valuable insights, our results underscore the 
uniqueness of a midbrain DA neuron. Indeed, the rapidity and specificity of MPP+ 
actions on DA axons are striking: toxin effects on mitochondria occur hours 
before microtubule tracks fall apart and before cell bodies are lost (Fig. 4.1). 
Moreover, neither non-DA mitochondria nor any other detectable type of moving 
particle is affected by toxin treatment, confirming the integrity of the microtubule 
tracks (Table 4.2). Together, these data point to an early and profound toxin-
mediated block of mitochondrial trafficking those results in mitochondrial 
redistribution away from the synapse back to the soma. Conceivably, damaged 
mitochondria moving toward the soma could deliver signals from the axon to the 
cell body, leading to the initiation of cell death. 
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Mitochondria undergo complex yet continual processes of fusion and 
fission that are critical for the exchange of organelle contents, repolarization, or 
degradation by autophagy [50]. Two PD-linked genes that are ubiquitously 
expressed have also been implicated in this process. Current data indicate that 
PINK1 is selectively stabilized on depolarized mitochondrial membranes [51]. 
This in turn acts as a signal for Parkin recruitment, which tags Pink-positive 
depolarized mitochondria for destruction via autophagy [51-53]. The latter studies 
would predict that following MPP+ treatment and bioenergetic declines, PINK1 
will be stabilized and Parkin will then be recruited to the PINK-tagged organelles 
before the appearance of autophagic puncta in DA axons. One caveat to this 
model, however, is that the previous studies were conducted in cell lines. A 
recent report examining PINK1 recruitment of Parkin in bona fide neurons did not 
see depolarization-mediated Parkin recruitment or autophagy [54]. Thus, other 
mechanisms may also contribute to the induction of these processes in neurons. 
In addition to its role in monitoring mitochondrial dynamics [7], PINK1 
might directly affect mitochondrial motility since it also forms a complex with Miro 
and Milton [8]. The latter proteins are known to recruit kinesin to the mitochondria 
and promote motility along microtubule tracks [9]. Recently, an ROS-
independent, redox dependentprotein termed HUMMR (hypoxia upregulated 
mitochondrial movement regulator) was discovered that also interacts with Milton 
and Miro to influence mitochondrial movement and direction [55]. Knockdown of 
HUMMR decreased anterograde movement of mitochondria and increased 
retrograde movement [55]. Given that MPP+-disrupted mitochondria exhibited 
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decreased anterograde and increased retrograde movement and that only the 
redox protectants NAC and GSHEE prevented these axonal effects, it may be 
possible that HUMMR, in conjunction with PINK1/Milton and Miro, plays a role in 
this process. Although MPP+-decreased m may be sufficient to reduce and 
alter mitochondrial movement, whether these or other transport-associated 
proteins play ancillary roles awaits future studies. 
A recent study suggests that somal and dendritic DA mitochondria occupy 
only 40% of the area of non-DA mitochondria [43]. Our cross-sectional 
measurements of mitochondria in DA axons versus non-DA axons mirror these 
results, with DA mitochondria being only 40% of the size of their non-DA 
counterparts (Table 4.2). Most importantly, axonal DA mitochondria exhibit an 
instantaneous velocity that is almost three times slower than non-DA 
mitochondria (Table 4.2). The validity of these observations is underscored by 
the use of two different mechanisms to measure mitochondrial properties (MTR 
and mtDendra2) (Table 4.2) with essentially the same results. Moreover, since all 
measurements were taken from within the same axonal fields, even if absolute 
numbers were affected by experimental conditions, the actual results are relative 
to each other. Presumably, this reflects inherent differences in DA axonal 
mitochondria themselves; perhaps a unique outer membrane protein interacts 
with a scaffolding protein that, in turn, binds to a slower motor. Alternatively, DA 
axons might be slightly narrower, slowing larger organelles and potentially 
contributing to their smaller size. Thus, in addition to producing a transmitter 
prone to oxidation [45] and reliance upon L-type Ca2+ channels that appear to 
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drain ATP resources [56], DA neurons might also be less effective at delivering 
mitochondria to sites of high energy usage such as synapses. 
Redistribution of mitochondria away from sites of high ATP usage would 
lead to axonal impairment, loss of synaptic connectivity, and hence loss of 
function. Although mitochondrial redistribution may not be the sole trigger of 
axonal dysfunction, it occurs early and is consistent with increased mitochondrial 
staining in the cell body (data not shown). This study, together with the large 
amount of evidence suggesting that PD is associated with axonal “dying-back,” 
underscores the necessity of developing therapeutics aimed at axons as well as 
cell bodies so as to preserve circuitry and function. Because NAC pretreatment 
not only prevented mitochondrial dysfunction but also preserved neurites and cell 
bodies, NAC or drugs like it may serve a future therapeutic role. 
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Table 4.1 - Effects of substrates, inhibitors, and  
anti-oxidants on MPP+-disrupted mitochondrial  
axonal transport.        
Motile mitochondria (%)    
Control   18.41 ± 3.62     
MPP+      8.25 ± 1.34 a     
          + Glucose    6.19 ± 1.26   
          + Csp3I- II       10.96 ± 2.58   
          + Gö6976    6.16 ± 3.42      
          + EGTA     4.80 ± 2.70      
          + SP600125         4.63 ± 0.63      
          + MnTBAP        9.49 ± 1.51        
   
          + NAC   18.62 ± 3.53b    
          + GSHEE  15.49 ± 3.10b     
 
Numbers are mean ± SEM, ap<0.05 compared to Control,  
bp<0.05 compared to MPP+. Concentration: MPP+ (2 µM),  
Glucose (20 mM), Csp3I-II (Caspase-3 inhibitor II, 5 µM),  
Gö6976 (500 nM), EGTA (2.5 mM), SP600125 (10 µM), 
MnTBAP(100 µM), NAC (N-acetylcysteine, 2.5 mM),  
GSHEE (5 mM).  
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Table 4.2 - DA axons exhibit unique mitochondrial and vesicular 
characteristics 
           DA                 non-DA 
  
 Density‡              8.89 ± 0.86   9.50 ± 0.82 
 Moving particles‡              1.93 ± 0.22   2.49 ± 0.24*  
 Speed (µm/s)    
MTR    0.28 ± 0.05   0.79 ± 0.07** 
   mtDendra2  0.30 ± 0.02   0.61 ± 0.11** 
 Cross area (µm2)   
                                MTR               1.07 ± 0.12   2.52 ± 0.11** 
                                mtDendra2     0.94 ± 0.06                        2.17 ± 0.47* 
 Ψm (AU)    58.5 ± 3.22   65.2 ± 4.08  
  Synaptic vesicles 
 Moving particles‡  3.93 ± 0.30   5.71 ± 0.63*  
 Speed (µm/s)  0.56 ± 0.05   0.52 ± 0.03 
  All particles  
 Moving particles‡  6.35 ± 1.22   6.79 ± 0.48   
 Speed (µm/s)  0.12 ± 0.01   0.14 ± 0.01  
‡ (#/100 µm). Numbers are mean ± SEM, *p<0.05, **p<0.001 compared to DA 
neurons. For MTR studies, 33 dishes from 11 independent experiments were 
evaluated; for mtDendra2 studies, eight dishes from four independent 
experiments were assessed. For synaptic vesicles, three dishes from three 
independent experiments were assessed. When measuring all particles, seven 
dishes from seven independent experiments were measured.  In all cases 3-5 
axons per dish were analyzed. 
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Table 4.3 - MPP+ did not affect mitochondrial number, speed or size in non-
DA axons                                                      
 Control                  MPP+   
 Moving particles (#/100 µm)              
MTR  2.49 ± 0.24   2.01 ± 0.23  
mtDendra2 1.92 ± 0.61   2.48 ± 0.14 
 Speed (µm/s)    
MTR   0.79 ± 0.07   0.71 ± 0.09 
   mtDendra2 0.61 ± 0.11   0.65 ± 0.19 
 Cross area (µm2)   
                                 MTR           2.52 ± 0.11   2.36 ± 0.19 
                                 mtDendra2  2.17 ± 0.47   2.57 ±0.46 
 
Numbers are mean ± SEM.  For MTR studies, 33 dishes from 11 independent 
experiments were evaluated; for mtDendra2 studies, eight dishes from four 
independent experiments were assessed. In all cases 3-5 axons per dish were 
analyzed. 
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Figure 4.1 - Neurite degeneration, microtubule disruption, and autophagy 
precede DA cell death following MPP+ treatment. (A) Dissociated DA neurons 
were treated with 1 M MPP+ for indicated times and then fixed and 
immunostained with rabbit polyclonal anti TH antibody. (B) Quantification of TH-
positive cell bodies and neurites remaining after toxin treatment. Numbers of TH-
positive cell bodies and neurites were counted using Stereo Investigator. 
Neurites were significantly reduced after 12 hours of treatment, whereas the 
number of cell bodies did not significantly change until 24 hours. Data denote the 
mean + SEM of representative determinations made in three independent 
experiments. (C) Integrity of microtubule tracks was assessed by measuring 
tubulin fragmentation before and after MPP+ treatment. Compartmented axons 
(described below) were fixed after 3, 6, and 24 hours of MPP+ treatment and 
stained with antibodies directed against AcTub and TH. Beading is seen as early 
as 6 hours (insert, arrowheads) and fragmentation at 24 hours (arrow). (D) TH-
positive axons with fragmented acetylated tubulin were quantified. One hundred 
to three hundred TH-positive axons were counted per dish and three dishes were 
counted per group. (E) Integrity of microtubule tracks was also assessed by 
transfecting tubulin-mCherry into DA/GFP cultures at DIV6. Following the 
addition of 2 mM MPP+, live images were acquired at the indicated times. (F) 
Tubulin intensity was expressed as percentage control. Mean + SEM made in 
three independent experiments, *p0.05, **p0.001, compared to 0 hours; #p0.05, 
compared to DA at 24 hours. (G) Autophagy was assessed by introducing a 
GFP-tagged LC3 expression clone at DIV6 and treating DA neurons 1 day later 
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with 2 M MPP+.The formation of LC3-positive granules was measured as 
indicated by immunostaining. Lower panels show LC3 fluorescence within TH-
positive axons before (top) and after (bottom) toxin treatment. For clarity, only 
LC3 fluorescence in axons is shown. (H) The number of TH-positive neurons with 
at least three LC3-GFP granules was counted and expressed as percentage of 
all neurons that were both TH positive and LC3-GFP positive, regardless of 
whether the LC3-GFP signal in these neurons was diffuse or punctuate. Mean + 
SEM in three independent experiments, *p0.05. In all bar graphs, hatching 
indicates toxin treatment. Scale bars: (A,C,E) 10 m (G) 1 m. 
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Figure 4.2 – MPP+ rapidly decreases mitochondrial movement in DA axons 
as shown by mtDendra2. (A) Diagram of microchamber device. (B) Transmitted 
light image of segregated axons derived from DIV12 DA/GFP cultures in the top 
panel, GFP fluorescence in the middle panel, and the merged image in the 
bottom panel showing TH-positive and TH-negative axons in same field. (C) 
Immunostaining of the axonal side with TH, the axonal marker Tau, and the 
dendritic marker MAP2. Tau but not MAP2 positive processes is present on 
axonal side. Scale bar, 10 m. (D) mtDendra2 colocalizes with TMRE. Despite 
presence of nonconverted mtDendra2, DA axon is easily identified. (E) Axonal 
movement of mitochondria. Mitochondria labeled with mtDendra2 were imaged 
for 5 min at 5 sec intervals after 30 min incubation with and without 2 M MPP+. 
For consistency, mitochondrial measurements were assessed near the axon 
terminal at least 2 mm away from the cell bodies. Resulting kymographs are 
shown below. (F) Number of moving mitochondria per 100 m length of axon 
was calculated. (G) Speed was calculated as described in Materials and 
Methods. (F,G) Mean + SEM, *p0.05, total of 17 (control) and 14 (MPP+-treated) 
axons derived from at least 7 dishes in 3 independent experiments. The 
anterograde speed (Antero) was decreased and the retrograde speed (Retro) 
increased as early as 30 min after MPP+ treatment. Scale bars: (B-D) 10 m. 
Hatching indicates toxin treatment. 
 
 
 
 
 
135 
 
 
136 
 
Figure 4.3 – MPP+ rapidly decreases mitochondrial movement in DA axons 
as shown by MitoTracker Red. (A) Axonal movement of mitochondria. 
Mitochondria were labeled with 25 nM MTR and imaged for 5 min at 5 sec 
intervals after 30 min of incubation with and without 2 M MPP+. Mitochondrial 
measurements were assessed as described in Figure 2. Resulting kymographs 
are shown below. (B) Total and moving mitochondria were counted and the rate 
of motile mitochondria was calculated. (C) Speed was calculated as described in 
Materials and Methods. (B,C) Mean + SEM, *p0.05, total of 114 (control) and 175 
(MPP+-treated) axons from 15 and 28 dishes in 13 independent experiments. 
Total length of control and MPP+-treated axons sampled were 10,716 and 16,732 
m, respectively, and the total numbers of mitochondria examined were 1762 
and 2632, respectively. The anterograde speed (Antero) was decreased and the 
retrograde speed (Retro) increased as early as 30 min after MPP+ treatment. 
Hatching indicates toxin treatment. 
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Figure 4.4 – MPP+ does not affect axonal movement of synaptic vesicles. 
Dissociated DA/GFP cultures were transduced with Syn-Cer lentivirus at DIV2. 
Vesicular movement was assessed on DIV12–13 before and after toxin 
treatment. (A) Although some vesicles were clumped and appeared to overlap 
mitochondria, individual vesicles labeled with Syn-Cer (arrows) were also 
visualized adjacent to mitochondria labeled with MTR (arrowheads). (B) 
Vesicular movement was observed for 5 min before and after 30 min of 
incubation with and without 2 M MPP+. Because of the smaller size of vesicular 
particles and the relative “dimness” of the cerulean emission, tracks of moving 
particles are shown below for clarity. (C,D) Quantification of moving particles (C) 
and speed (D) were determined as described in Materials and Methods. Scale 
bar: 10 m. Mean + SEM, ns, nonsignificant, total of 25 (control) and 38 (MPP+-
treated) axons from 4 and 5 dishes in 4 independent experiments. Total lengths 
of control and MPP+-treated axons sampled were 2247 and 3497 m, 
respectively. Hatching indicates toxin treatment. 
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Figure 4.5 - MPP+ rapidly leads to DA efflux. 3H-DA release assays were 
performed exactly as we have previously described except that 10 min treatment 
windows were used instead of 6 min [18]. (A) MPP+ dose response curve; EC50 
for DA release is 0.42 ± 0.04 µM (mean ± SEM). (B) MPP+-mediated DA release 
can also be assessed in segregated axons. Each chamber was briefly incubated 
with 3H-DA, washed extensively with PBS and then treated with or without 1 µM 
MPP+ for 10 min. Chambers were washed and then treated with 60 mM K+ to 
release vesicular contents and finally lysed to assess remaining DA levels [18]. 
Top panel, high K+ releases 50-60% of intracellular DA levels in control cell 
bodies and axons whereas, 1 µM MPP+ releases >95% (Bottom panel). Axon-
only chamber represented about 25% of transmitter levels in cell body chamber. 
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Figure 4.6 - MPP+ rapidly depolarizes DA mitochondria. (A) Mitochondria in 
axons from DA/GFP cultures were labeled with 25 nM TMRE and then assessed 
before and 30 min after MPP+ treatment. Scale bar: 5 m (B) MPP+ led to 
significant differences in ΔΨm as measured in arbitrary units (AU; arrows). (C) 
Cross sectional areas of mitochondria labeled with MTR were measured before 
and after toxin treatment using Image J particle analysis. Hatching indicates toxin 
treatment. (Mean ± SEM of representative determinations from three 
independent experiments, **p<0.001) 
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Figure 4.7 - NAC protects DA cell bodies and neurites from MPP+-induced 
degeneration. (A) Dissociated DA neurons were pretreated with 2.5 mM NAC for 
18 hours, treated with 2 µM MPP+ for 24 hours and then fixed and 
immunostained with rabbit polyclonal anti-TH antibody. Scale bar: 10 m (B) 
Quantification of TH-positive cell bodies and neurites. Cell bodies and neurites 
were significantly protected by NAC. (Mean ± SEM from three independent 
experiments, *p<0.05, compared to Control, #: p<0.05, ##: p<0.001, compared to 
MPP+) 
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Abstract 
 An emerging hypothesis in Parkinson’s disease (PD) is that dopaminergic 
(DA) neurons degenerate through a “dying back” axonopathy wherein 
degeneration begins in the distal axon and progresses over time towards the cell 
body. Impaired axonal transport also appears to play an early, pivotal role in PD. 
Thus processes that delay axonal transport dysfunction and/or axonal 
degeneration might slow PD progression. Previously, our lab has found that the 
WldS mouse mutant (“Wallerian degeneration-slow”), which exhibits delayed 
axonal degeneration after peripheral axonopathy, also protects DA terminal fields 
from the PD-mimetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in 
vivo. To understand the mechanisms underlying WldS-mediated axonal 
protection, we utilized compartmented chambers that enabled us to segregate 
axons from cell bodies and dendrites. Using these devices, we found that MPP+ 
impaired mitochondrial in DA axons and that WldS rescued MPP+-mediated 
impairment of mitochondrial transport in DA axons. Mechanistically, this appears 
to be the result of WldS-mediated protection from toxin-induced loss of 
mitochondrial membrane potential. These results extend WldS protection to CNS 
DA axons and suggest that WldS confers a gain-of-function phenotype that 
attenuates mitochondrial dysfunction. This study also underscores the necessity 
of developing therapeutics aimed at axons as well as cell bodies in order to 
preserve circuitry and function. 
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5.1  Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder in the U.S. The cardinal motor symptoms of PD include resting tremor, 
bradykinesia, rigidity, and abnormal gait [1-2]. These symptoms appear after 50-
70% [3-4] of striatal dopamine (DA) levels have been depleted and 30-50% [5-6] 
of the DA cells in the substantia nigra (SN) have died. Given that the severity of 
PD symptoms correlates better with loss of striatal DA [5] and because many 
postmortem studies show widespread axonal pathology [7,8], early axonal 
dysfunction may play a significant role in PD.  
Data from animal models of PD support the notion that DA axons are 
compromised prior to cell body loss. For example, transgenic mice expressing 
the PD-linked R1441G leucine-rich repeat kinase2 (LRRK2) mutation exhibited 
decreased DA terminal fields and increased dystrophic processes yet only 
modest changes were seen in the number of their SN neurons. [7]. In addition, 
mutant -synuclein proteins accumulate in the cell soma when overexpressed in 
cortical neurons suggesting that these mutants exhibit reduced axonal transport 
[8]. Support for this notion comes from data showing that vesicle-associated -
synuclein binds to the microtubule motor proteins kinesin and dynein [9], thereby 
affecting microtubule-dependent axonal transport. Another PD-linked gene, 
PINK1, a mitochondrially targeted kinase, can also form a complex with Miro and 
Milton [10], proteins known to recruit kinesin to the mitochondria and promote 
motility along microtubule tracks [11]. Finally, in some but not all model systems 
[12-13], the PD associated ubiquitin ligase, Parkin, is recruited to mitochondrial 
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membranes by stabilized PINK1. Through unknown mechanisms, Parkin then 
recruits autophagy machinery to the mitochondria [14] (mitophagy) presumably to 
clear dysfunctional organelles [15]. If the clearance system is overwhelmed, 
axonal degeneration may ensue [16]. 
Environmental toxins mimicking PD such as N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or its active derivative, 1-methyl-4-phenylpyridinium 
(MPP+) have also been shown to disrupt axonal function. For example, 
Herkenham et al., observed marked reductions of dopaminergic axons prior to 
the loss of nigral cell bodies following acute MPTP administration in monkeys 
[17]. Similarly, Meissner et al. reported an 80% loss of both the dopamine plasma 
membrane transporter (DAT) and DA levels in the macaque striatum following 
chronic MPTP delivery whereas only a 43% loss of DA cells was observed in the 
SN [18]. DA terminal loss is also the earliest event in murine MPTP models [19]. 
Using both the acute and chronic MPTP paradigms, Li and colleagues observed 
~25% cell body loss after treatment whereas DA terminals were decreased by 
~65-70% in either model [20]. Finally, a recent study reported a profound 
decrease (73%) in striatal DA following MPTP treatment whereas only a 9% 
decline of SN cells was observed [21]. In this same study, the GDNF receptor, 
RET, rescued the cells but not the terminal fields, re-confirming the basic 
observation that axons and cell bodies constitute separate compartments. These 
findings support the hypothesis that nigral neurons degenerate through a “dying 
back” axonopathy in which degeneration begins in the distal axon and proceeds 
over time towards the cell body [22-23]. 
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The question arises then as to what factor or signaling system might 
rescue axons from degeneration? One serendipitous protein is the spontaneous 
mouse mutant, Wallerian degeneration slow (WldS). WldS delays axonal 
degeneration about 10-fold from a wide variety of genetic and toxin-inducing 
stimuli in the peripheral nervous system (PNS) [24] and in several central 
nervous system (CNS) models of degeneration including animal models of PD 
[25-26]. For example, we have shown that WldS rescues 85% of DA axons for at 
least 7 days post MPTP treatment in vivo [27]. Not only does WldS protect DA 
terminal fields in vivo, the same holds true in vitro as demonstrated in Chapters 2 
and 3. Specifically, dissociated DA neurons prepared from WldS mice were also 
significantly protected from MPP+. WldS itself is a chimeric protein composed of 
the N-terminal 70 amino acids of the ubiquitination factor Ube4b followed by a 18 
amino acid linker region and the entire sequence of Nmnat1, a key enzyme in the 
biosynthesis of NAD+ [28]. In contrast to peripheral model systems [24], we saw 
that only the entire WldS fusion protein protected DA neurites, whereas Nmnat1, 
cytoplasmically targeted Nmnat1 or Nmnat3 did not (Fig. 2.3 and 3.2). 
Surprisingly, WldS constructs mutagenized for NAD+ synthesizing activity were 
just as effective as non-mutagenized WldS constructs (Fig. 2.5). These data 
suggest that increased NAD+ may not underlie the ability of WldS to rescue DA 
neurites from toxin effects. Given these significant attributes of WldS, 
understanding how the WldS fusion protein prevents axon degeneration is an 
important step towards identifying an intervention that would leave axons intact.     
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In order to more easily test the effects of WldS on DA axons we crossed 
WldS mice with genetically engineered mice expressing GFP in DA neurons 
(DA/GFP). The resulting WldS/DA/GFP mice were plated in microchamber 
devices that segregated DA axons from DA cell bodies. As shown previously 
[29], wild type mice rapidly lost mitochondrial motility in DA axons when 
challenged with MPP+. In contrast, WldS protected DA axons from MPP+-induced 
disruption in mitochondrial axonal transport, possibly through a direct action on 
the mitochondria.   
 
5.2  Materials and methods 
 
 All of the methods and materials for making the cell cultures and 
microchamber devices, imaging and quantifying axonal transport, measuring 
dopamine uptake and release, quantifying mitochondrial membrane potential 
(m) and length, measuring autophagy, and performing statistical analyses for 
these set of experiments were performed exactly as described for Chapter 4. 
Experiments were done on both DA/GFP and WldS-DA/GFP murine 
mesencephalic cultures prepared from embryonic day 14 Tg(TH-
EGFP)DJ76GSAT and C57Bl/OlaHsd-WldS-Tg(TH-EGFP)DJ76GSAT mice, 
respectively (Gene Expression Nervous System Atlas, National Institutes of 
Health, Bethesda, MD and Harlan, Bichester, UK). 
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5.2.1 Western Blotting 
Western blotting was done as described in Chapters 2 and 3, with the 
exception that PVDF membranes were probed with a mouse acetylated tubulin 
antibody (Sigma-Aldrich, Saint Louis, MO). As a loading control, PVDF 
membranes were also probed with mouse monoclonal anti-actin antibody 
(Sigma-Aldrich) followed by an HRP-linked mouse secondary antibody (Jackson 
Immunoresearch, West Grove, PA).   
 
 
5.2.2 Immunohistochemistry 
To determine where WldS is expressed in DA axons, WldS primary 
mesencephalic cultures were plated in microchamber devices, fixed and then 
stained with rabbit WldS antibody (1:500, gift of M.P. Coleman) and Alexa488 
anti-rabbit antibody (1:500, Molecular Probes, Carlsbad, CA). In some cases, 
axons were incubated with 25 nM MitoTracker Red (MTR; Invitrogen, Carlsbad, 
CA) prior to fixation. To determine acetylated tubulin levels specifically in DA 
axons, primary midbrain cultures plated in microchamber devices were fixed and 
stained with mouse acetylated tubulin (1:1000, Sigma-Aldrich) and Cy3 anti-
mouse antibodies (1:500, Molecular Probes, Carlsbad, CA).  
 
5.2.3  Fragmentation of axons 
Fragmentation of axons was assessed by sampling five non-overlapping 
fields in the axonal part of the chamber. The number of DA/GFP axons was 
153 
 
counted using an unbiased grid system in ImageJ. The degree of change in axon 
structure was quantified as: (Number of fragmented axons) / (Number of total 
axons). 
 
5.3  Results 
 
5.3.1 WldS prevents MPP+-induced changes in axonal structure  
We have previously reported that DA terminal fields but not cell bodies of 
WldS mice are protected against MPTP injury [27] in vivo and MPP+ toxicity in 
vitro (Fig. 2.1). To confirm and extend these observations in our modified 
microchamber system, primary mesencephalic cells obtained from both DA/GFP 
and WldS-DA/GFP mice were grown in compartmented chambers and treated 
with 2 M MPP+ on DIV14. Chambers were subsequently fixed at various time 
points and examined for axonal integrity using GFP fluorescence as a relevant 
indicator of DA axons. Like MPTP treated WldS mice [27] or MPP+-treated 
dissociated DA neurons (Fig. 2.1), DA axons from DA/GFP/WldS mice were 
significantly protected from toxin treatment at all time points, most prominently at 
12 h (Fig. 5.1A,B). Thus, in vitro as in vivo [23], WldS protects DA axons from 
MPTP/MPP+ toxicity. 
Studies in cultured cerebellar granule cells have shown that WldS cultures 
have higher baseline levels of acetylated tubulin compared to WT cultures [30]. 
To determine if WldS DA neurons exhibit higher levels of microtubule acetylation, 
we either stained DA axons with anti-acetylated tubulin or prepared lysates from 
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midbrain cultures for western blotting. Neither immunocytochemical techniques 
(Fig. 5.1C) nor western blots (Fig. 5.1D,E) detected differences in acetylated 
tubulin levels between WT and WldS cultures. Thus, differences, if any, are not 
apparent in WldS compared to wild type DA axons or cultures 
 
5.3.2 WldS protein is present in DA mitochondria  
Many studies have shown that the WldS fusion gene is primarily localized 
in the nucleus [31]. This is also true in DA neurons in the SN [27].  Despite the 
abundance of WldS in the nucleus, it can also be found in other locations 
including axons [32]. “Extranuclear” WldS is reportedly associated with small 
membranous structures including mitochondria [33]. To determine the subaxonal 
expression pattern of WldS, we labeled compartmentalized axonal mitochondria 
with MTR and then fixed and stained for WldS with the Wld18 antibody. WldS was 
axonally distributed in pleo-morphic globular organelles which significantly 
overlapped with MTR (56.14 + 15 % overlap) (Fig. 5.2). Other studies have not 
identified any overt structural differences in mitochondria derived from WT or 
WldS mice [34-35]. In agreement with these findings, we did not see any 
differences in baseline mitochondrial density, number of moving mitochondria, 
mitochondrial velocity, mitochondrial length, or m between DA/GFP and Wld
S-
DA/GFP DA axonal mitochondria (Table 1). These data indicate that extranuclear 
WldS is readily distributed to DA axons where it is associated with mitochondria 
but does not outwardly change any of their parameters. 
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5.3.3  WldS prevents MPP+-induced changes in axonal mitochondrial 
transport 
 Recently, we demonstrated that MPP+ rapidly decreases mitochondrial 
transport in DA axons [29]. Because WldS significantly co-localized with axonal 
mitochondria (Fig. 5.2), we tested whether mitochondrial transport was altered in 
WldS-DA/GFP axons. As we previously reported, MPP+ decreased the numbers 
of moving mitochondria in DA/GFP axons by 50% within 30 min of treatment (Fig. 
5.3A,B). We also confirmed in DA/GFP axons that MPP+ treatment decreased 
the number and speed of moving mitochondria in the anterograde direction but 
increased speed in the retrograde direction (Fig. 4.3) [29]. In contrast, numbers 
of moving mitochondria in WldS-DA/GFP axons were not affected by MPP+ 
treatment nor were there any differences in their anterograde or retrograde 
motility (Fig. 5.3A,B). Similarly, no change in mitochondrial velocity was 
measured following MPP+ treatment in either the anterograde or retrograde 
direction in WldS-DA/GFP cultures (Fig. 5.3A,C). Thus WldS prevents the rapid 
and directed effect of MPP+ on DA axonal mitochondria.  
 To determine whether WldS had an effect on other types of organelles 
particularly synaptic vesicles, DA/GFP and WldS-DA/GFP cultures in 
microchamber devices were transduced using a lentivirus expressing 
synaptophysin fused in frame with cerulean (Syn-Cer). We did not observe any 
significant difference between DA/GFP and WldS-DA/GFP axons in terms of the 
number of moving Syn-Cer particles per 100 m length of axon (2.88 + 0.17 and 
3.02 + 0.44, respectively). Not surprisingly, no significant difference was apparent 
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in the velocity of the Syn-Cer particles in DA/GFP and WldS-DA/GFP cultures 
(0.47 + 0.02 m/sec and 0.41 + 0.08 m/sec, respectively) as well. Despite 
MPP+-induced changes in mitochondrial axonal transport, (Fig. 5.3A,B) [29], 
MPP+ did not affect synaptophysin motility and velocity in wild type or WldS 
cultures (Fig. 5.3D,E), indicating that the effect of WldS is specific for 
mitochondria.  
  
5.3.4 WldS prevents MPP+-induced decreases in axonal mitochondrial 
membrane potential 
Because MPP+ leads to a rapid loss of m, in DA axons [18], we tested 
whether WldS affected that process. Compartmentalized DA/GFP and WldS-
DA/GFP axons were labeled with the sensitive m indicator 
tetramethylrhodamine ethyl ester (TMRE) before acquiring baseline images. After 
30 min of toxin treatment, m was significantly reduced in DA/GFP but not 
WldS-DA/GFP axonal mitochondria (Fig. 5.4A,B). Similarly there were no 
significant differences in the size of WldS-DA/GFP mitochondria following MPP+ 
treatment (not shown). Thus, MPP+ rapidly depolarized DA/GFP mitochondria but 
not WldS-DA/GFP. 
To test whether WldS also protects DA mitochondria from other types of 
depolarizing agents, we treated DA/GFP and WldS-DA/GFP axons with carbonyl 
cyanide m-chlorophenyl-hydrazone (CCCP), which depolarizes mitochondria by 
acting  as an uncoupler [36]. DA/GFP and WldS-DA/GFP axons were labeled with 
TMRE and images were acquired at baseline as well as at 15 and 30 minutes 
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after the addition of CCCP. CCCP reduced m in both DA/GFP and Wld
S-
DA/GFP axonal mitochondria at both time points examined (Fig. 5.4C,D), but 
there was a significant attenuation observed in WldS DA mitochondrial axons at 
30 minutes. Taken together, these results show that WldS attenuates processes 
that alter mitochondrial membrane potential such as blocking complex I (MPP+) 
or uncoupling membrane potential (CCCP)   
 
5.3.5 WldS protects DA neurons against MPP+-induced autophagy 
Decreases in m can induce mitophagy (autophagy of mitochondrial 
organelles) [32]. Given that we [18] and others [33] have shown that MPP+ 
induces autophagy in DA neurons, we tested whether WldS could prevent 
autophagy in this model system. Using GFP-labeled LC3 (microtubule-
associated protein 1, light chain 3; also known as ATG8), as a frequently used  
marker of autophagy, we confirmed our previous observation that LC3-GFP 
puncta were visible as early as 3 hours after MPP+ treatment [29] (Fig. 5.5A). In 
contrast, WldS cultures transduced with LC3-GFP maintained the normal diffuse 
cytoplasmic distribution even after MPP+ treatment (Fig. 5.5). These data are 
consistent with the evidence that WldS prevents MPP+-induced mitochondrial 
membrane depolarization and this in turn prevents the induction of mitophagy.  
 
5.4 Discussion 
Numerous studies  suggest that axonal dysfunction precedes cell body 
death in many neurodegenerative disorders, especially PD. Halting or delaying 
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axonal degeneration would allow DA axons to stay “wired up” and hence, 
functional. Because WldS dramatically rescued DA terminal fields from MPTP in 
vivo [27] and since WldS also protects DA neurites in vitro (Fig. 2.1), we used 
optical, cellular and molecular techniques to demonstrate that WldS protects DA 
axons by maintaining m, mitochondrial motility, and mitochondrial velocity such 
that autophagic processes are not activated.   
What is the mechanism by which WldS protects DA terminals?  Although 
many studies have emphasized that both Nmnat1 and cytoplasmically re-directed 
Nmnat can protect axons in many peripheral model systems, few studies have 
tested how WldS protects DA neurons from PD-linked genes and/or toxins. 
Studies on peripheral nervous system models attribute the protective phenotype 
of WldS to its Nmnat portion. In vitro studies have shown that overexpression of 
Nmnat1 by itself protects axons from many mechanical, genetic or toxin-induced 
injuries [24, 37]. However, transgenic animals expressing nuclear Nmnat1 are 
less neuroprotective than WldS [38-39]. In part, this might be due to where 
Nmnat1 is expressed [24] since cytoplasmically [40] or axonally targeted Nmnat1 
[33] in vivo was equally if not more effective than WldS at protecting axons 
against injury. Interestingly, in either case Nmnat1 was expressed at higher 
levels in the mitochondrial fraction compared to nuclear Nmnat1 [33, 40]. 
Nmnat3, a mitochondrially expressed isoform of Nmnat, also showed comparable 
levels of protection to WldS when expressed in vivo, unlike native Nmnat1 [39]. 
Even the WldS fusion protein was more effective in vivo when it was targeted to 
the cytoplasm and it also showed higher levels of expression in the mitochondria 
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than native WldS [32]. Although we used the original WldS animals (albeit crossed 
with DA/GFP), our study shows that extranuclear WldS partially colocalizes with 
axonal DA mitochondria,  attenuating MPP+-induced changes in m, 
mitochondrial motility and mitochondrial velocity. Thus, the present findings are 
consistent with the observations that WldS might regulate or affect an important 
mitochondrial process.  
Data supporting this idea comes from a differential proteomics approach 
comparing WT and WldS striatal synaptosomes [34]. Sixteen proteins were found 
to be differentially expressed, eight of which were localized to the mitochondria. 
These included the VDAC2, a pore forming protein in the outer mitochondrial 
membrane which essentially serves as a metabolite exchanger [41]. The latter, 
although not part of the mPTP is thought to play a role in regulating it [42]. Of the 
three known VDACs each has a unique phenotype. For instance, VDAC2 inhibits 
apoptosis whereas VDAC1 is an activator of apoptotic processes [43]. Given the 
complexity of their protein structure and the numerous isoform-specific protein-
protein interactions, there might be many target points for WldS/VDAC2 
interactions.  Nonetheless, since DA synapses would comprise a significant 
proportion of striatal synaptosomal preparations, the changes in mitochondrial 
proteins in WldS versus WT re-enforce the notion that WldS might be acting 
directly at the level of the mitochondria to prevent axonal dysfunction.  
Mitochondria undergo complex fission and fusion processes in part to 
ensure a healthy pool of organelles [44]. Towards this end it is thought that 
depolarized mitochondria are quickly culled from the pack and marked for 
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destruction, possibly through the stabilization of PINK1 on the outer 
mitochondrial membrane followed by the recruitment of Parkin and other 
mitophagic components [45]. Earlier studies done in wild type or WldS superior 
cervical ganglion (SCG) cultures found that, as expected, WldS protected SCG 
neurites from vinblastine treatment. But for the first time, it also showed that WldS 
prevented a highly significant loss of m which occurred in wild type cultures 
[35]. In other studies using sciatic nerve preparations, axon degeneration was 
ascribed to activation of the mitochondrial permeability transition pore (mPTP) 
[46]. Opening of the mPTP is thought to trigger m, ROS, loss of ATP, and 
release of pro-apoptotic factors, amongst other things [47]. In this same sciatic 
nerve study, WldS prevented the activation of mPTP after axons were cut but was 
unable to protect axons from pharmacological agents directly activating the pore 
[46]. These results prompted Barrientos et al. to propose a model in which WldS 
acts upstream of the mitochondria to prevent the opening of the mPTP [46].  
Barrientos et al. also showed that both pharmacologic and genetic 
manipulation of cyclophilin D, a functional component of the mPTP, were able to 
prevent axon degeneration [46]. Recently Thomas et al. reported that cyclophilin 
D knockout mice were significantly resistant to MPTP toxicity, raising the 
possibility that this mechanism might hold true for this PD-linked toxin as well. 
However, several caveats for this idea exist. The authors found that knocking out 
cyclophilin D was ineffective against subacute or chronic MPTP models and only 
partially effective at rescuing SN neurons in the acute model. Although it 
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appeared that there was some preservation of DA terminal fields, that area most 
relevant to this study, densitometry was also not done in these animals [48].   
 Perhaps the most direct question is whether MPP+ activates the mPTP in 
the dissociated culture system. Earlier experiments using bongkrekic acid and/or 
cyclosporine A to prevent mPTP opening following MPP+ did not rescue DA 
neurons from cell death [Lotharius and O’Malley, unpublished observation]. It will 
be important to repeat these experiments using our current model system to see 
whether cyclosporine A prevents MPP+-induced depolarization of DA axonal 
mitochondria. 
This work and our previous work show that MPP+ rapidly inhibits the 
motility of DA mitochondria [29]. Despite the MPP+-induced decrease seen in 
m, increasing ATP levels, blocking ROS production or JNK, PI3K or PKC 
pathways, or preventing rises in cytoplasmic calcium levels did not rescue 
mitochondrial motility. To date, the only pharmacologic agents that prevented 
MPP+-induced mitochondrial immobility were  N-acetylcysteine (NAC) and 
membrane permeable GSH [29]. Given the prevalence of redox-sensitive 
proteins in the mitochondria and the close connection between redox balance 
and membrane potential [49], redox regulation of depolarization might facilitate 
interactions between the bioenergetic membranes and homeostatic processes 
such as mitophagy. WldS could potentially work at the level of the mPTP by 
blocking pore activation or at the level of the mitochondrial thioredoxin/ or 
glutaredoxin/ reductase systems to maintain a reduced state [50]. Since 
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cyclophilin D itself is regulated by redox potential, mPTP could be indirectly 
strengthened via a WldS effect on redox potential. 
Although maintenance of mitochondrial function may not be the sole 
trigger of axonal dysfunction, our data shows that it plays an early and pivotal 
role in the degeneration of axons. This study, together with the large amount of 
evidence suggesting that PD is associated with axonal “dying-back,” underscores 
the necessity of developing therapeutics aimed at axons as well as cell bodies so 
as to preserve circuitry and function. Understanding how WldS protects axons is 
important in designing potential interventions that can delay or halt axonal 
dysfunction and ensuing disease progression.   
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Table 5.1 - WT and WldS have similar mitochondrial characteristics 
 DA  Non-DA  
 WT  WldS  WT  WldS  
Density  8.89 + 0.86  8.43 + 0.48  9.5 + 0.82  10.08 + 0.59  
Moving particles/ 
100 mm  1.93 + 0.22  2.00 + 0.19  2.49 + 0.24*  2.78 + 0.19*  
Speed (mm/s)  0.28 + 0.05  0.23 + 0.20  0.79 + 0.07**  0.87 + 0.06**  
Length (mm)  1.19 + 0.04  1.17 + 0.09  2.28 + 0.12  2.7 + 0.19  
m(AU)  50 + 8.37  49.55 + 10.3  55.14 + 9.14  48.70 + 6.32  
Mean + SEM, total of 40 (control) and 82 (MPP+-treated) axons derived from 8 
independent experiments, *p<0.05, **p<0.01 
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Figure 5.1 - WldS prevents changes in axonal structure after MPP+. (A) 
Integrity of DA/GFP and WldS-DA/GFP DA axons was assessed before and after 
MPP+ treatment. Compartmented axons were fixed after 12, 24, and 48 hours of 
MPP+ treatment. (B) Fragmentation of DA axons was quantified. Mean + SEM 
made in three independent experiments, *p<0.05, **p<0.001. (C) Levels of 
acetylated tubulin (Ac-tub) were assessed by staining DA/GFP and WldS-
DA/GFP DA axons with acetylated tubulin antibody. No significant difference in 
baseline acetylated tubulin levels was evident between WT and WldS axons. (D) 
Western blot shows similar expression levels of acetylated tubulin in lysates from 
WT and WldS primary mesencephalic cultures. (E) Quantification of the western 
blots done on cell lysates from three independent experiments, Mean + SEM.  
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Figure 5.2 - WldS partially colocalizes to axonal mitochondria. 
Sublocalization of WldS was assessed by labeling mitochondria with MTR and 
staining WldS DA axons with Wld18 antibody. Approximately 50% colocalization 
of Wld18 staining and MTR signal was observed (arrows).  
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Figure 5.3 – WldS protects against MPP+-induced changes in mitochondrial 
axonal transport. (A) WldS-DA/GFP DA mitochondria labeled with MTR were 
imaged for 5 min at 5 sec intervals after 30 min incubation with and without 2 M 
MPP+. For consistency, mitochondrial measurements were assessed near the 
axon terminal at least 2 mm away from the cell bodies. Resulting kymographs 
are shown below. (B) Number of moving mitochondria per 100 m length of axon 
was calculated. Mean + SEM, total of 40 (control) and 82 (MPP+-treated) axons 
derived from 8 (control) and 16 (MPP+-treated) dishes in 8 independent 
experiments. (C) Vesicular movement as measured using Syn-Cer was observed 
for 5 min before and after 30 min of incubation with and without 2 M MPP+. 
Quantification of moving particles was determined as described in Materials and 
Methods. Mean + SEM. A total of 42 (control) and 80 (MPP+-treated) axons from 
8 (control) and 16 (MPP+-treated) dishes in 8 independent experiments.  
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Figure 5.4 - WldS prevents MPP+-induced decreases in axonal 
mitochondrial membrane potential. (A) Mitochondria in axons from DA/GFP 
and WldS-DA/GFP cultures were labeled with 25 nM TMRE and then assessed 
before and 30 min after MPP+ treatment. (B) MPP+ led to significant differences 
in ΔΨm in DA/GFP mitochondria but not in Wld
S-DA/GFP mitochondria. Mean ± 
SEM of representative determinations from six independent experiments, 
**p<0.001 (C) Mitochondria in axons from DA/GFP and WldS-DA/GFP cultures 
were again labeled with 25 nM TMRE and then assessed before and 30 min after 
2 m CCCP treatment. (D) CCCP led to decreases in ΔΨm in DA/GFP and Wld
S-
DA/GFP mitochondria at 15 and 30 minutes after addition of toxin, but WldS-
DA/GFP attenuated the effects of CCCP 30 minutes after treatment. Mean ± 
SEM of representative determinations from six independent experiments, 
*p<0.05. 
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Figure 5.5 - WldS prevents mitophagy after MPP+. (A) Autophagy was 
assessed by introducing a GFP-tagged LC3 expression clone at DIV6 and 
treating DA neurons 1 day later with 2 M MPP+. The formation of LC3-positive 
granules (arrow) was measured as indicated by immunostaining. Right panels 
show LC3 fluorescence within TH-positive axons after toxin treatment. (B) The 
number of TH-positive neurons with at least three LC3-GFP granules was 
counted and expressed as percentage of all neurons that were both TH positive 
and LC3-GFP positive, regardless of whether the LC3-GFP signal in these 
neurons was diffuse or punctuate. Mean ± SEM in three independent 
experiments, *p<0.05.  
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Conclusions and Future Directions 
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6.1  Conclusions 
Axonal dysfunction and impaired axonal transport may play a key role in 
PD. This notion is dramatically supported by our earlier work showing that the 
WldS fusion protein completely rescued DA terminal fields from in vivo MPTP 
toxicity [1]. The current findings confirm and significantly extend these studies in 
vitro exploring mechanisms underlying WldS actions against additional PD-linked 
toxins. Our findings identify a novel role of WldS in DA axons that is independent 
of its NAD+-synthesizing activity and further emphasizes a novel gain of function. 
Moreover, our new observations point to a significant role of WldS in maintaining 
or delaying changes in mitochondrial membrane bioenergetics .Finally, this 
dissertation reinforces the notion that DA neurons are more susceptible in the 
pathogenesis of PD due, in part, to unique characteristics of their mitochondria 
that are smaller and slower than their counterparts.  
Given the many studies showing that Nmnat at least partially protects 
axons from a variety of insults both in the CNS but especially the PNS, our 
studies showing that Nmnat1, Nmnat3 and cytoplasmically-targeted Nmnat1 
cannot protect DA axons from two different types of parkinsonian mimetics were 
surprising. Although it might be argued that the transduced levels of each variant 
were insufficient to protect DA neurites, the fact that the same if not greater 
numbers of DA neurons were transduced (Chapter 2), that expressed protein 
levels were the same (Fig. 2.3), and most importantly, that the same lentiviral 
preparations rescued DRG neurites from vincristine treatment, indicates that 
insufficient Nmnat is not the cause. Most studies also suggest that Nmnat’s 
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NAD+-synthesizing ability is essential in protecting axons [2-3], yet this did not 
seem to be the case in DA neurites either (Fig. 2.5). Moreover, while exogenous 
NAD+ did protect cell bodies and neurites against MPP+, its neuroprotective 
effect was additive with that of WldS suggesting that it was acting through a 
different mechanism (Fig. 2.8). Finally, even though WldS protected DA neurites 
from 6-OHDA, neither Nmnat1 nor exogenous NAD+ did so, again suggesting 
that the entire WldS fusion protein is required for protection of DA neurites. Taken 
together, these findings argue that WldS plays a different role in DA neurons than 
it does in certain CNS or PNS neurons. 
What is different about DA neurons? Besides producing a 
neurotransmitter that is prone to oxidation [4], DA neurons have long, thin-
caliber, poorly myelinated axons. Typically, such axons use more energy to 
generate action potentials than more highly myelinated neurons [5]. Thus DA 
axons may require more energy making them more susceptible to energy loss 
than axons requiring less [5]. This idea is consistent with data demonstrating 
preferential effects on DA neurons of inhibitors of mitochondrial complex 1 such 
as MPP+ and rotenone and even 6-OHDA, leading to ROS, loss of m, and 
eventually loss of ATP [6]. DA neurons also exhibit a greater dependence on L-
type Ca2+ channels than most neurons which can lead to deleterious amounts of 
intracellular calcium and increased stress on mitochondria [7]. Moreover, DA 
neurons have fewer mitochondria [8] and, as shown here [17], DA axonal 
mitochondria are smaller and move along the axon slower than mitochondria in 
non-DA neurons. These unique characteristics of DA neurons suggest that 
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protection of these neurons may employ a different type of mechanism(s), 
potentially one that protects DA mitochondria from bioenergetic challenges.  
WldS is predominantly seen in the nucleus, but here, we present evidence 
that the WldS protein partially colocalizes with DA axonal mitochondria (Fig. 5.2), 
similar to what has been reported by others [9]. Thus, WldS can protect against 
axonal degeneration by preserving mitochondrial function. In support of this, we 
saw that WldS DA axonal mitochondria maintained their motility after MPP+ 
treatment. WldS also protected axonal DA mitochondria against MPP+-induced 
decrease in mitochondrial membrane potential (m) and attenuated the effect of 
carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) on m. In addition, Wld
S 
neurites were protected against 6-OHDA, which our lab has previously reported 
to cause ROS generation and a rapid decrease in m of DA neurons [10]. 
These results are consistent with data showing that WldS cultures maintain their 
m and have intact neurites after vincristine treatment [11]. Taken together, our 
findings and other studies underscore the role of mitochondria in the 
neuroprotective phenotype of WldS. 
 So how does WldS protect DA axonal mitochondria? A recent study has 
shown that WldS was able to regulate the mitochondrial permeability transition 
pore (mPTP) and prevent calcium release, ATP loss, oxidative stress and 
release of proteins involved in axonal degeneration in sciatic nerve explants [12]. 
In addition, the mPTP inhibitor, promethazine, was reported to prevent MPTP-
induced loss of SN DA neurons [13]. Because CCCP and oxidative stress can 
also induce mitochondrial permeability transition [14-15], one potential model is 
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that WldS protects axons by inhibiting mPTP activation, mitochondrial 
depolarization, and all the subsequent complications of mitochondrial 
dysfunction. WldS can potentially prevent opening of the mPTP in response to 
toxin injury in two ways. First, WldS can affect the mPTP through direct action on 
the pore since one of the proteins that was upregulated in WldS striatal 
synaptosomes is VDAC2 [16], which has been shown to regulate the mPTP [17]. 
The second way that WldS can affect pore opening is suggested by our findings 
that NAC and GSHEE protect against MPP+-induced loss of mitochondrial 
motility. Since WldS has a similar phenotype, we hypothesize that WldS might 
affect redox balance such that the pore is less likely to open and hence can 
withstand various challenges in a more robust fashion. Future studies will 
continue to explore this role of WldS in protecting DA axons from degeneration. 
 
 
Figure 6.1 – Proposed model of how WldS protects DA axons from PD 
mimetics. Modified from Toman and Fiskum, 2011 [18].  
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6.2  Future Directions 
 
6.2.1 Does disruption of the mitochondrial permeability transition pore in 
DA neurons inhibit the protective effect of WldS?  
 We hypothesize that WldS protects DA axons by inhibiting mitochondrial 
permeability transition (Fig. 6.1). To test this idea, we propose to examine if 
exogenous activation of mPTP causes degeneration of DA axons and if WldS 
cultures protect DA axons against this type of insult. Atractyloside (ATR) 
stimulates mPTP by inducing a conformational change in the adenine nucleotide 
translocator (ANT) [19]. Thus, we can utilize ATR for these experiments. We can 
also test if primary midbrain cultures from cyclophilin D knockout mice [20], which 
are available from Jackson Laboratories, are protected against 6-OHDA and 
MPP+-induced toxicity and if this protection is similar to the WldS phenotype. 
Alternatively, we could use knockdown approaches to similarly manipulate the 
levels of cyclophilin D. 
To determine whether delayed mPTP activation is intrinsic to WldS 
mitochondria, we can also examine the effect of ATR on the m of WT and Wld
S 
DA axonal mitochondria. If our model holds true, we predict that ATR will have 
less effect on axonal degeneration and m in Wld
S DA axons compared to WT.  
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6.2.2 Does WldS protect DA neurons through an effect on glutathione 
levels?  
 Similar to our findings in WldS cultures, pretreatment of DA axons with the 
redox-sensitive neuroprotectants NAC and GSHEE protected against MPP+-
induced changes in mitochondrial motility and DA neurite and cell body loss. 
Thus, it is worth investigating if WldS cultures protect in a similar manner as NAC 
and GSHEE by determining if WT and WldS exhibit similar levels of reduced 
GSH. Reduced GSH may be visualized using Ellman's reagent or bimane 
derivates such as monobromobimane [21]. Another way to measure glutathione 
is through the use of redox-sensitive green fluorescent protein (roGFP) [22]. 
These proteins have the advantage of enabling one to quantify the glutathione 
redox potential in live cells, but have the disadvantage of having poor sensitivity 
and slow response to redox potential changes. An alternative approach is to 
utilize the Grx1-roGFP2 fusion protein developed by Gutscher et al. [23]. Using 
this fusion protein, the authors were able to measure glutathione redox potential 
in different cellular compartments with high sensitivity and temporal resolution 
while still allowing one to conduct experiments in live cells. More importantly this 
construct, and one devised to look at thioredoxin function, can be targeted to the 
mitochondria allowing redox measurements of that organelle [23]. 
 Aside from comparing baseline levels of GSH in WT and WldS mice, we 
can also examine how GSH affects the WldS phenotype by decreasing GSH 
levels in WldS mice.  Treatment of animals with buthionine sulphoximine (BSO), 
an inhibitor of gamma-glutamylcysteine synthetase, has been shown to lower 
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tissue GSH concentration [24]. If treating WldS animals with BSO abrogates their 
protective effect against 6-OHDA or MPTP, this will suggest that maintenance of 
GSH levels plays a role in the neuroprotective phenotype of WldS. 
 
6.2.3 How does WldS protect against 6-OHDA-mediated 
neurodegeneration?  
 We saw that WldS protects DA cell bodies and neurites against 6-OHDA-
mediated toxicity through an Nmnat-independent mechanism. However, the 
exact mechanism by which WldS protects against 6-OHDA has not been fully 
explored. Data from this lab has shown that ROS production from 6-OHDA 
upregulates the unfolded protein response (UPR) and causes p53-dependent cell 
death through two parallel pathways [25]. 6-OHDA also causes a rapid decrease 
in m of DA neurons [10]. Accordingly, the following questions need to be 
addressed: (1) Does WldS protect DA neurons against oxidative stress? (2) Does 
WldS protect DA neurons against upregulation of UPR? (3) Does WldS protect DA 
neurons against p53 activation? (4) Does WldS protect against 6-OHDA-
mediated decrease in m? 
 
6.2.3.1  Does WldS protect DA neurons against oxidative stress? 
Mouse embryonic fibroblasts from WldS mice were protected against 
paraquat, a PD-linked toxin known to generate ROS [26]. 6-OHDA has also been 
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shown to rapidly and robustly generate ROS in DA cell bodies [10], This 
emphasizes the need to examine if WldS protects against 6-OHDA-mediated 
increases in oxidative stress. Measuring ROS in axons can be difficult but 
recently other studies have shown that MitoSox, a dye derived from DHE, has 
the sensitivity to see changes in situ using optical imaging techniques. Thus, 
using MitoSox, we can quantify the generation of ROS in the mitochondria of WT 
and WldS DA axons in response to 6-OHDA treatment.  
 
6.2.3.2 Does WldS protect DA neurons against upregulation of UPR?  
 6-OHDA causes upregulation of proteins associated with the unfolded 
protein response (UPR) [27]. Since Nmnat has been suggested to have 
chaperone activity [28-29], it is possible that WldS prevents 6-OHDA injury by 
inhibiting the initiation of the UPR. To determine if WT and WldS cultures have 
differential regulation of UPR after 6-OHDA, we can probe WT and WldS primary 
midbrain cultures with antibodies for UPR markers at baseline and at the 
appropriate time points after addition of 6-OHDA. Two UPR markers that would 
be interesting to utilize for this purpose are ATF3, which is an early UPR maker, 
and CHOP, which is a late UPR marker. If WldS has a chaperone-like activity 
similar to Nmnat1, we would predict that WldS will prevent the upregulation of the 
both ATF3 and CHOP.  
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6.2.3.3 Does WldS protect DA neurons against activation of p53? 
 Our lab has recently shown that 6-OHDA-generated ROS induces DNA 
damage and causes cell death through a p53-dependent mechanism. 
Intriguingly, primary midbrain cultures from p53 knockout mice were almost 
completely protected from 6-OHDA toxicity both at the level of the cell body and 
neurites [25]. To investigate if WldS’ neuroprotective effect is potentially mediated 
by p53, WT and WldS primary midbrain cultures can be stained with phospho-p53 
antibody before and after 6-OHDA treatment to determine if these two types of 
cultures have a similar induction of p53 activity after addition of toxin. Because 
our previous work showed that DA cell bodies, but not neurites, of Puma (p53-
upregulated mediator of apoptosis)-null mice were protected against 6-OHDA 
[25], we would predict that if WldS prevents the activation of p53, it will also 
prevent the upregulation of its downstream effector, Puma.   
 
6.2.3.4 Does WldS protect against decreased mitochondrial membrane 
potential due to 6-OHDA toxicity? 
 Since 6-OHDA causes a rapid decrease in m in DA cell bodies [10], we 
can test if WldS can prevent against changes in m from 6-OHDA injury. This 
can be done in a similar manner as described in Chapter 4 and 5 in MPP+-
treated cultures through the use of tetramethylrhodamine ethyl ester (TMRE) as 
a m indicator dye. Since we hypothesize that Wld
S protects axons through its 
action on the mitochondria, we predict that WldS will also prevent changes in m 
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axonal DA mitochondria after 6-OHDA treatment. Data from these proposed 
experiments will help elucidate how WldS protects against predicted 6-OHDA-
induced axonal injury.  
 
6.2.4  Does 6-OHDA affect axonal mitochondrial dynamics?  
MPP+ and 6-OHDA cause DA cell death through distinct cell death 
mechanisms [10], thus what we’ve shown for MPP+ may not necessarily be the 
same processes triggered by 6-OHDA toxicity. One similarity however is that, like 
MPP+, 6-OHDA causes a rapid decrease in m in DA cell bodies [10]. This 
implies that 6-OHDA may also cause mitochondrial dysfunction and/or 
mitochondrial permeability transition. Hence, one can investigate if 6-OHDA also 
causes (1) a decrease in mitochondrial motility, (2) slower anterograde 
mitochondrial velocity, and (3) faster retrograde mitochondrial velocity, before 
disruptions in microtubule stability are observed using the microchamber device 
utilized in the experiments described in Chapter 4. We predict that 6-OHDA 
effects on axon transport will overlap to a significant extent with those of MPP+. 
As previously described, Burke and colleagues found that, similar to MPTP, 6-
OHDA also lead to depletion of striatal nerve terminals followed by retrograde 
degeneration of neurons in the SN and that WldS protected against this loss of 
DA terminals [30]. Thus, we predict that WldS will also protect DA mitochondria 
against 6-OHDA-induced perturbations in mitochondrial dynamics.  
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Taken together this will further support our hypothesis that mitochondrial 
transport dysfunction leads to axonal degeneration in DA neurons. Therefore, 
these data suggest that while MPP+ and 6-OHDA cause DA cell death through 
distinct mechanisms, they may share a common mechanism of axonal 
degeneration.    
 
6.2.5 Does MPTP affect mitochondrial motility and velocity in vivo?  
 The current work shows that MPP+ decreases mitochondrial motility, 
changes mitochondrial velocity, and decreases m in DA axons in vitro. 
Extending results from cellular systems to in vivo systems is essential in further 
establishing if MPP+-specific effects in mitochondrial health and dynamics are 
integral to the role of axonal degeneration in PD pathogenesis. In vivo imaging of 
the basal ganglia at the resolution needed to see individual mitochondrion is 
impossible at the moment given its location deep in the animal’s brain. However, 
an ex vivo approach would get us one step closer. To do this, parasagittal brain 
slices can be prepared from DA/GFP mice such that DA projections from the SN 
to the striatum are preserved. Protocols exist for maintaining brain slices in a 
special chamber that allows for live imaging. MTR can be used to label 
mitochondria and time lapse confocal imaging to monitor mitochondrial dynamics 
to determine if our in vitro observations are recapitulated ex vivo. Problems with 
this approach might be the excessive mitochondrial labeling seen with MTR and 
the difficulty in assigning mitochondria to DA/GFP axons. Alternatively, we can 
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image mitochondria by crossing DA/GFP mice with transgenic mice that express 
CFP in the mitochondria (Thy1-mitoCFP-H) [31]. One caveat of this approach is 
the potential difficulty of identifying the cyan fluorescence signal labeling the 
mitochondria in the background of a green fluorescence signal signifying DA 
axons.  Another way to assess mitochondrial transport is by using static time 
points in an intact animal. MTR can be stereotactically injected into either the SN 
or the striatum before treating mice with an acute regimen of MPTP. Mice can 
then be sacrificed at a range of time points after MPTP administration. Changes 
in mitochondrial transport can be visualized by assessing differences in the 
distribution of MTR distally and proximally from the site in injection, whether it is 
the striatum or SN, in fixed parasagittal brain slices. Regardless of the 
experimental approach utilized, we predict that mitochondrial motility and velocity 
are affected by MPTP in brain slices, similar to the effect of MPP+ in primary 
mesencephalic cultures.     
 
6.2.6 Does WldS protect against MPTP-induced changes in mitochondrial 
motility and velocity in vivo?  
 As our findings on the effect of MPP+ on mitochondrial motility are seen in 
vitro, we need to confirm that the protection seen in WldS axonal DA 
mitochondria is replicated in vivo. We can test if WldS protects against MPTP-
induced changes in mitochondrial motility and velocity in vivo by using the 
method(s) described in the previous section using WldS-DA/GFP brain slices. 
191 
 
Given that WldS protected axons against MPTP in vivo [1], we predict that WldS 
will also protect midbrain projections to the striatum against MPTP-induced 
changes in mitochondrial health and dynamics.  
 Our work has shed light on the role of mitochondria in MPP+-mediated DA 
axonal degeneration and how WldS protects against this injury in vitro. The 
results of these proposed experiments will further establish how WldS protects 
DA axons against both MPTP and 6-OHDA and extend our in vitro results in vivo. 
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